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Background. Hepatic encephalopathy (HE) produces a wide spectrum of 
nonspecific neurological and psychiatric manifestations. Mild HE that does not 
produce disorienting in time/space or asterixis is called covert HE (CHE). It occurs in 
20%–80% of patients with cirrhosis. While significant progress has been made in 
understanding the importance of CHE, to date there is no consensus guidelines 
regarding the screening procedures for CHE and all the recognized techniques, 
although more or less sensitive and objective, require some kinds of equipment. 
Furthermore, the diagnosis of CHE can be confounded by other factors (as chronic 
alcohol misuse or HCV infection), which can cause cognitive alterations. It is also 
important to identify CHE in patients awaiting liver transplantation (LT) for the 
proper interpretation of cognitive disorders that may occure after transplantation. 
Infact, the influence of LT on mental performance is debated; as is the role of 
pretransplant HE. Notable, recent data on LT suggest that the cognitive dysfunction 
may not be totally reversible. Another important issue regards the treatment of CHE, 
in particular the effect of treatments on gut microorganism and ammonia production 
by microbial activity. HE treatment with prebiotics, antibiotics and probiotics, 
generally evidences a reduction of photogenic/ ammoniagenic bacteria and an 
increase in neurocognitive tests and mental status in patients. Nevertheless from a 
strictly microbiological point of view, little is known about the dynamics, interaction 
and metabolite production of the main bacterial groups in liver diseases. 
Aims. The present study aims to: 1) test a simple verbal psychometric test, 
called Animal Naming Test (ANT1), in the detection of CHE; 2) to evaluate the role 
of alcohol misuse, HCV infections, diabetes, aging and level of education as potential 
confounding factors in the diagnosis of CHE; 3) to evaluate the time course of the 
neuropsychological and electroencephalogram (EEG) features of patients with 
cirrhosis before and after LT with respect to prior HE and 4) to investigate how the 
HE treatments (by the use of lactulose, rifaximin and a probiotc mixture) affects gut 
microbial composition, determining changes in ammonia production. 
Materials and methods. For Aim 1: 208 healthy subjects and 327 consecutive 
patients with cirrhosis underwent the ANT1. Patients with cirrhosis were assessed by 
the Psychometric Hepatic Encephalopathy Score (PHES), a subgroup of 146 
underwent also a quantified EEG and 95 the Critical Flicker Frequency. 202 patients 
were followed up for the occurrence of overt HE (OHE) and death. For Aim 2: a 
comprehensive neuropsychological profile and EEG spectral parameters were 
obtained in six age-matched groups of 30 subjects each: (i) HCV-related hepatitis 
without cirrhosis, (ii) chronic alcohol abusers, (iii) patients with HCV-related 
cirrhosis, (iv) alcohol-related cirrhosis, (v) cirrhosis not related to alcohol or HCV 
and (vi) healthy subjects. Cirrhotic patients were matched for MELD score. For Aim 
3: the study population included 65 patients with cirrhosis on the transplant waiting 
list; 23 had a history of OHE. Each patient underwent an extensive psychometric 
assessment (10 tests, including paper and pencil tests and a computerized test) and an 
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EEG before and 9 to 12 months after LT. EEGs were analyzed spectrally, and the 
mean dominant frequencies were obtained. For Aim 4: independent batch culture 
fermentations with controlled pH (6.8) were inoculated with fecal samples from six 
patients with cirrhosis (age 66±3.3 years; Child-Pugh A n=5 and B n=1); average 
MELD score 9±2.8). Seven different treatments with lactulose, rifaximin and VSL#3 
or their combination were performed. Microbial populations were enumerated using 
flow cytometry Fluorescent in Situ Hybridization, while an ammonia concentration 
was determined at 0, 4, 10 and 24 hours. 
Results. Aim 1: in controls, the ANT1 was found relevantly affected only by 
extremely low levels of education (<8 yrs) and old age (>80 yrs; p<0.001). Thus, an 
age and education adjusted criterion was obtained (S-ANT1). Patients with CHE had 
significantly lower S-ANT1 than the unimpaired ones (12±0.4 vs 16±0.7; p<0.001). 
By ROC analysis, two thresholds of 10 and 15 animals were obtained, producing a 
Scoring System (0=S-ANT1>15, 1=S-ANT1 10-15, 2=S-ANT1<10 sensitivity 83%, 
specificity 84%, respectively vs. PHES) that was correlated both to PHES (p<0.0001) 
and EEG (p=0.007). In the follow up, the S-ANT1 resulted to have prognostic value 
on the risk of OHE and death, so that a prognostic index could be computed. Aim 2: 
the factor ‘cirrhosis’ was associated with low Phonemic Verbal Fluency (PVF) and 
Difference between Trail Making Test B and A (TMT B-A) (p<0.001). Chronic 
alcohol misuse was associated with low PVF, TMT (B-A), Memory with Interference 
Task at 10 (ITM 10) and 30s (ITM 30) (all p<0.05). An interaction was found 
between the factors ‘cirrhosis’, ‘alcohol misuse’ and tests (p<0.01). HCV hepatitis 
reduced ITM 10 (p<0.05), but no interaction was found between ‘cirrhosis’, ‘HCV 
infection’ and tests (p= 0.14). The EEG parameters were mainly influenced by 
‘cirrhosis’ (p<0.05), and EEG alterations were more pronounced in patients with 
alcoholic cirrhosis (p=0.04). Aim 3: Patients with a history of OHE before LT had 
worse cognitive performances (p<0.001) and EEG performances in comparison with 
their counterparts with a negative history. They also showed greater cognitive 
improvement after LT (p<0.01); however, their global cognitive performance 
remained slightly impaired (p <0.01). After LT, EEGs normalized for 98% of the 
patients (p <0.01), regardless of any history of OHE. Aim 4: Lactulose treatment 
significantly increased total bacteria, Bifidobacteria and Fecalibacterium prausnitzii 
after 5 hours (p≤0.05); in contrast Rifaximin and a probiotic mixture (VSL#3) have 
no significant effect. After 24 hours the combination of lactulose/Rifaximine/VSL#3 
significantly increased total bacteria and Bifidobacteria. At time 5 h, lactulose 
significanly reduced ammonia, whereas rifaximin had no significant effect. VSL#3 
alone had never significant affect in reducing ammonia, whereas at 24 h, in 
combination with lactulose and rifaximin, reduced significantly ammonia.  
Conclusions. The ANT1 is an easy first-line measure useful for detection of 
CHE. The diagnosis of CHE should considered the concomitant presence of alcohol 
misuse and low educational level, which had a synergistic effect with cirrhosis in 
damaging cognitive functions, and thus they should be considered as possible 
confounders when testing for CHE. After LT, patients with a history of HE showed 
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greater improvements than patients with a negative history, but their global cognitive 
function remained slightly worse; in contrast, EEGs normalized in both groups. 
Regarding HE treatments, microbial modulation by prebiotic, antibiotic and probiotic 
differently affect the population dynamics and metabolism. The strong increase in 
beneficial bacteria, reduction of ammonia and regulation of metabolite production 
seen using lactulose and its combination with VSL#3, emphasize the importance of 









































 Stato dell’arte. L’encefalopatia epatica (EE) è caratterizzata da un ampio 
spettro di manifestazioni aspecifiche, sia neurologiche che psichiatriche. Un EE lieve 
tale da non indurre disorientamento spazio-temporale o asterissi è definita “EE non 
conclamata”, e si manifesta nel 20%-80% dei pazienti con cirrosi epatica. Sebbene 
siano stati compiuti notevoli progressi nella comprensione dell'importanza dell’EE 
non conclamata, non esistono, ad oggi, linee guida condivise in materia di screening. 
Inoltre, tutte le tecniche di diagnosi universalmente riconosciute, anche se più o meno 
sensibili ed obiettive, richiedono l’utilizzo di una qualche forma di strumentazione. 
La diagnosi di CHE dovrebbe anche tener conto di altri fattori (come l’abuso alcolico 
o l’infezione da virus C), in grado di per sé di causare alterazioni cognitive, che 
potrebbero agire da fattori di confondimento. Un’altra problematica aperta in ambito 
di EE non conclamata è la reversibilità delle alterazioni cognitive, caratteristiche dei 
pazienti con storia di EE, dopo trapianto di fegato che è tuttora controversa. Studi 
recenti sembrano suggerire che le alterazioni cognitive caratteristiche dei pazienti con 
storia di EE non siano completamente reversibili. Anche il ruolo del microbiota 
intestinale nella patogenesi e quindi nella terapia dell’EE non è del tutto noto. Studi 
recenti hanno dimostrato che le terapie dell’EE, che si basano su prebiotici, 
antibiotici e probiotici, determinano una riduzione di batteri ammoniagenici e un 
concomitante miglioramento dei test neurocognitivi e dello stato mentale dei pazienti. 
Tuttavia, da un punto strettamente di vista microbiologico, poco si conosce circa le 
dinamiche e l'interazione tra i principali gruppi di batteri e come si modifica la 
produzione di ammonio a seguito della somministrazione di tali terapie.   
Scopi dello studio. Il presente studio si propone di: 1) testare un test 
psicometrico verbale, chiamato Animal Naming Test (ANT1), nella diagnosi di EE 
non conclamata; 2) valutare il ruolo dell’abuso alcolico cronico, dell’infezione da 
virus, del diabete, dell’invecchiamento e del livello d’istruzione come potenziali 
fattori di confondimento nella diagnosi di EE non conclamata; 3) di valutare 
l'andamento temporale neuropsicologico ed elettroencefalografico dei pazienti con 
cirrosi prima e dopo trapianto di fegato, in relazione alla presenza o meno di una 
storia di EE prima del trapianto e 4) di valutare come i trattamenti dell’EE (quali il 
lattulosio, la rifaximina e il probiotico VSL#3) modifichino la composizione 
microbica intestinale e determinino cambiamenti nei livelli di ammonio. 
Risultati. Obiettivo 1: nei controlli l’ANT1 è risultato influenzato in modo 
significativo solo da livelli di istruzione estremamente bassi (<8 anni di scolarità) e 
da un’età molto avanzata(> 80 anni; p<0,001). Sono, quindi, stati calcolati i punteggi 
aggiustati per età e livello d’istruzione (S-ANT1). I pazienti cirrotici con EE non 
conclamata avevano uno S-ANT1 significativamente inferiore dei pazienti senza EE 
(12±0,4 vs 16±0,7; p<0.001). L’analisi delle curve ROC ha permesso di ottenere due 
valori soglia dell’S-ANT1, di 10 e 15 animali/minuto, ed è stato costruito un sistema 
di Scoring (0=S-ANT1> 15, 1=S-ANT1 10-15, 2=S-ANT1<10 con sensibilità 83% e 
specificità 84%) che è risultato ben correlato sia con la PHES (p<0,0001) che con 
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l’EEG (p=0.007). Nel follow-up, lo S-ANT1 è risultato avere un valore prognostico 
sia sul rischio di EE conclamata che sulla mortalità ad un anno. Obiettivo 2: il fattore 
'cirrosi' è risultato associato sia con il Phonemic Verbal Fluency (PVF) che con la 
Differenza tra Trail Making Test B e A (TMT) (B-A) (p<0.001). L’abuso alcolico 
cronico è risulato associato con un bassi punteggi al PVF, al TMT (B-A) e ai test di 
Memoria di interferenza a 10 (ITM 10) e 30 s (ITM 30) (tutti p<0.05). E’ stata trovata 
un'interazione tra i fattori «cirrosi',' abuso alcolico 'e test (p<0,01). Il virus C 
determina una riduzione dell’ITM 10 (p<0,05), ma nessuna interazione è stata trovata 
tra i fattori 'cirrosi', 'infezione da HCV' e test (p=0.14). I parametri EEG sono risultati 
principalmente influenzati dal fattore 'cirrosi' (p<0,05). Obiettivo 3: i pazienti con una 
storia di EE, prima del trapianto, hanno avuto performance cognitive ed EEG 
peggiori rispetto alla controparte senza storia di EE (p<0.001). Ma, dopo il trapianto, 
hanno mostrato un miglioramento cognitivo maggiore (p<0.01); tuttavia, la loro 
performance cognitiva globale rimane lievemente compromessa (p<0,01). Dopo il 
trapianto, l’EEG si normalizza nel 98% dei pazienti (p<0.01), indipendentemente 
dall’avere una storia di EE. Obiettivo 4: il trattamento con lattulosio aumenta 
significativamente il numero totale dei batteri, dei Bifidobatteri e del Fecalibacterium 
prausnitzii, rispetto al controllo e dopo 5 ore (p≤0.05); al contrario sia Rifaximina che 
il probiotico VSL#3 non hanno alcun effetto significativo. Dopo 24 ore la 
combinazione di lattulosio/Rifaximina/VSL#3 aumenta significativamente il numero 
totale dei batteri e i bifidobatteri. Per quanto riduarda la produzione di ammonio, il 
lattulosio riduce in modo significativo l’ammonio, mentre la Rifaximina non ha 
effetti significativi. Il probiotico VSL#3 da solo non ha mai un effetto nel ridurre 
l’ammonio, mentre in combinazione con lattulosio e rifaximina a 24 ore lo riduce 
significativamente. 
Conclusioni. L’ANT1 è uno strumento utile e facile da somministrare per il rilievo 
dell’EE non conclamata. La diagnosi dell’EE non conclamata dovrebbe inoltre tener 
conto della concomitante presenza di un abuso cronico alcolico e di un basso livello 
d’istruzione, che possono avere un effetto sinergico con la cirrosi nell’alterare le 
funzioni cognitive, e dovrebbero quindi essere considerati come fattori di 
confondimento nella diagnosi di EE non conclamata. Dopo trapianto di fegato, i 
pazienti con una storia di EE prima del trapianto presentato nel post-trapianto un 
miglioramento maggiore rispetto pazienti senza storia di EE, ma la loro performance 
cognitiva globale rimane un po’ alterata; al contrario, l’EEG si normalizza in quasi 
tutti i pazienti. Per quanto riguarda l’influenza delle terapie dell’EE sul microbiota 
intestinale dei pazienti con cirrosi, i prebiotici, gli antibiotici e i probiotici 
influenzano in modo diverso la dinamica e il metabolismo delle popolazioni 
batteriche. Il forte aumento dei batteri benefici e la riduzione dell’ammonio favoriti 
dal lattulosio e dalla sua combinazione con rifaximina e VSL#3, sottolineano 








3.1 HEPATIC ENCEPHALOPATHY 
 
Hepatic encephalopathy (HE) is a frequent complication and one of the most 
debilitating manifestations of liver disease, severely affecting the lives of patients and 
their caregivers. Unless the underlying liver disease is successfully treated, HE is 
associated with poor survival and a high risk of recurrence (1). Even in its mildest 
form, HE reduces health-related quality of life and is a risk factor for bouts of severe 
HE.  
 
3.1.1 Definition and epidemiology  
 Hepatic encephalopathy is a brain dysfunction caused by liver insufficiency 
and/or portal-systemic shunting; it manifests as a wide spectrum of neurological or 
psychiatric abnormalities ranging from subclinical alterations to coma (2). This 
definition is based on the concept that encephalopathies are ‘‘diffuse disturbances of 
brain function’’ and that the adjective ‘‘hepatic’’ implies a causal connection to liver 
insufficiency and/or perihepatic vascular shunting (1). 
In patients with cirrhosis, fully symptomatic overt HE (OHE) is an event that 
defines the decompensated phase of the disease, such as variceal bleeding or ascites 
(3). Overt hepatic encephalopathy is also reported in subjects without cirrhosis with 
extensive PSS. The prevalence of OHE at the time of diagnosis of cirrhosis is 10%–
14% in general (4,5), 16%–21% in those with decompensated cirrhosis (3), and 10%–
50% in patients with transjugular intrahepatic portosystemic shunt (TIPS) (6). The 
cumulated numbers indicate that OHE will occur in 30%–40% of those with cirrhosis 
at some time during their clinical course and in the survivors in most cases repeatedly 
(7). The risk for the first bout of OHE is 5%–25% within 5 years after cirrhosis 
diagnosis, depending on the presence of risk factors, such as other complications to 
cirrhosis (MHE or CHE, infections, VB, or ascites) and probably diabetes and 
hepatitis C (8,9). Subjects with a previous bout of OHE were found to have a 40% 
cumulative risk of recurring OHE at 1 year (10), and subjects with recurrent OHE 
have a 40% cumulative risk of another recurrence within 6 months, despite lactulose 
treatment. 
 
3.1.2 Clinical presentation and classification  
Hepatic encephalopathy produces a wide spectrum of nonspecific neurological 
and psychiatric manifestations (11). In its lowest expression, HE alters only 
psychometric tests oriented toward attention, working memory (WM), psychomotor 
speed, and visuospatial ability, as well as electrophysiological and other functional 
brain measures (12). As HE progresses, personality changes, such as apathy, 
irritability, and disinhibition, may be reported by the patient’s relatives, and obvious 
alterations in consciousness and motor function occur. Disturbances of the sleep-
wake cycle with excessive daytime sleepiness are frequent, whereas complete 
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reversal of the sleep-wake cycle is less consistently observed (13). Patients may 
develop progressive disorientation to time and space, inappropriate behavior, and 
acute confusional state with agitation or somnolence, stupor, and, finally, coma. The 
recent ISHEN (International Society for Hepatic Encephalopathy and Nitrogen 
Metabolism) consensus uses the onset of disorientation or asterixis as the onset of 
OHE (13). 
Hepatic encephalopathy should be classified according to all of the following four 
factors (11):  
1) According to the underlying disease, HE is subdivided into I) Type A resulting 
from ALF; II) Type B resulting predominantly from portosystemic bypass or 
shunting; III) Type C resulting from cirrhosis.  
2) According to the severity of manifestations. The continuum that is HE has been 
arbitrarily subdivided. For clinical and research purposes, a scheme of such grading is 
provided (Table 1). Operative classifications that refer to defined functional 
impairments aim at increasing intraand inter-rater reliability and should be used 
whenever possible.  
3) According to its time course, HE is subdivided into I) Episodic HE II) Recurrent 
HE denotes bouts of HE that occur with a time interval of 6 months or less; III) 
Persistent HE denotes a pattern of behavioral alterations that are always present and 
interspersed with relapses of overt HE.  
4) According to the existence of precipitating factors, HE is subdivided into I) Non 
precipitated or II) Precipitated, and the precipitating factors should be specified.  
 
 







3.1.3 Pathogenesis of hepatic encephalopathy: a complex network of 
interdependent organ systems  
The complex HE pathogenesis is not yet fully elucidated. Ammonia was first 
implicated in the pathogenesis of HE. Ammonia is a by-product of nitrogen 
metabolism, and its formation in the body is predominantly a consequence of the 
action of the vast number of urease-producing bacteria located in the gut. Urease is a 
bacterial enzyme that catalyzes the hydrolysis of urea to carbamate and ammonia. 
Ammonia is absorbed into the hepatic portal circulation and transported to the liver 
where, under normal physiological conditions, it enters the urea cycle and is 
metabolized. Ammonia that bypasses this primary fate is subsequently ‘picked up’ 
and detoxified by glutamine synthetase (GS), an enzyme found in the hepatocytes 
surrounding the hepatic vein (as well as in muscle and astroglial cells), which 
catalyses the conversion of ammonia and glutamate to glutamine (14). Whilst the 
liver is critical in the homeostatic control of blood ammonia levels, other organs such 
as the brain, muscle and kidney are also known to play a role in regulating them. 
Insult to the liver, whether acute or chronic in nature, reduces its capacity to 
metabolize ammonia and this exerts an ammonia burden on extrahepatic tissues 
which can result in hyperammonaemia up to five times that of normal blood ammonia 
levels. In the context of liver failure, the brain, and more specifically, astrocytes, act 
as an alternative metabolic pathway for ammonia. In the brain, hyperammonemia 
promotes astrocyte swelling and impairment of neurotransmission. In chronic liver 
failure, astrocytes typically exhibit morphological features of Alzheimer type II 
astrocytosis, which include a large swollen nucleus, prominent nucleolus, 
margination of the chromatin pattern and significant enlargement of the cytoplasm. 
First evidence of the role of ammonia in the pathogenesis of HE date back to 1893, 
when Hahn and colleagues demonstrated the induction of an encephalopathic state in 
dogs following the formation of a surgical shunt, known as Eck's fistula, which 
served to divert nitrogen-rich blood from the portal vein directly to the inferior vena 
cava, therein bypassing the liver. Six weeks post-operatively, the dogs began to 
exhibit increased levels of aggression, irritability, ataxia, as well as experiencing 
seizures and eventually lapsing into coma especially following ingestion of an 
ammonia-rich meal (15).  
Later, some studies founded discrepancies in the direct correlation between ammonia 
concentration and the severity of HE in patients with cirrhosis (16). These findings 
have contributed to the general consensus that whilst ammonia has an irrefutable, and 
key role in the pathogenesis of HE, it may not be solely responsible for the 
neurocognitive sequelae and other factors might be contributing, such as 
inflammation and hyponatremia (17). Infection is an important precipitant of HE (16) 
and has been shown to worsen the progression of HE and cerebral edema in patients 
with ALF (18), and proinflammatory cytokines seem to act synergistically with 
ammonia in causing cerebral edema (19) in acute liver failure as well as cirrhosis 
(20). Overactive neutrophils with excessive degranulation activity and enhanced 
production of inflammatory cytokines may also play a role in this pathogenesis. 
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Additionally, alterations in toll-like receptor 4, a receptor responsible for recognition 
of gram-negative bacteria, may be at least partly responsible for the inflammatory 
state in the cirrhotic patient. Polymorphisms of this receptor that occur in cirrhotic 
patients may increase both the risk of infection and the risk of HE (21). Thus, 
ammonia is only a single component in a multifactorial disease process.  
 
3.1.4 Gut microbiota: its role in hepatic encephalopathy 
 
Gut-liver axis 
The liver receives 70% of its blood supply from the intestine via the portal 
vein, thus it is continually exposed to gut-derived factors including bacterial 
components, endotoxins and peptidoglycans. The liver is of paramount importance in 
generating an effective innate immune response and is the first organ to encounter 
bacteria or toxins absorbed from the gut. Multiple hepatic cells, including Kupffer 
cells, sinusoidal cells, biliary epithelial cells and hepatocytes, express innate immune 
receptors known as pathogen-recognition-receptors (PRRs) that recognized and 
respond to bacteria express components (pathogen-associated molecular patterns 
[PAMPs]) from the gut (22). PRRs may be located on the cell surface (e.g.Toll-like 
receptor 4, TLR4), endolysosome (e.g. TLR9) or cytosol (e.g. nucleotide-binding 
oligomerization domain 1, NOD1). PAMP(s) recognition stimulates intracellular 
signaling pathways and transcription factors to induce a battery of genes encoding 
inflammatory molecules. PAMP-induced inflammatory response is indispensable for 
combating invading bacteria. 
Cirrhosis is associated with both intestinal bacterial overgrowth (23,24) and 
dysbiosis, as autochthonous bacteria are decreased and potentially pathogenic 
bacteria increased (25,26). Several causes underlie such abnormalities in cirrhosis, 
including impaired gut motility, reduced bile flow, impaired gastric acid secretion, 
and altered IgA secretion and antimicrobial molecules (27;28). These abnormalities 
might primarily contribute to dysbiosis by facilitating the oral microbiome transition 
to small and large intestine, as bacterial species of buccal origin are enriched in the 
fecal microbiome of cirrhotic patients (26). Both animal and human studies shows 
that dysbiosis induces intestinal inflammation and gut leakiness. Therefore, 
dysbiosis-induced intestinal inflammation may contribute to pathological bacterial 
translocation (BT). The mechanism triggering intestinal inflammation in cirrhosis is 
unknown, but hitherto unidentified microbial products/metabolites might be involved. 
Conversely, a compromised intestinal defense might contribute not only to dysbiosis, 
but also to enhanced pathological BT. Thus, cirrhosis-associated dysbiosis 
contributes to intestinal homeostasis disruption by altering the intestinal immune 
system. Increased intestinal permeability allows microbial products/bacteria to 
translocate from the intestinal lumen to extraintestinal organs and spaces including 
mesenteric lymph nodes (MLNs), portal and systemic circulation. While microbial 
products likely escape from the intestinal lumen to the lamina propria via a 
paracellular route through disrupted tight junctions, living bacteria translocate via a 
transcellular route (transcytosis) (29). Translocation of viable bacteria is a hallmark 
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of cirrhosis, in particular during decompensation (29). In cirrhosis, impaired liver 
clearance contributes to an accumulation of PAMPs, and bacteria in the systemic 
circulation (24,30).  
The liver forms a second vascular barrier for eliminating commensal bacteria that 
have escaped from the gut. In animal models of liver disease and gut dysfunction the 
liver is unable to capture escaped gut commensal bacteria, which then leak into the 
systemic circulation, resulting in a robust host nonmucosal immune response (30).  
Danger-associated molecular patterns (DAMPs) originating from damaged 
liver tissue also increase during acute and chronic liver diseases (31). Microbial 
products and DAMPs activate receptors of the innate immune system contributing to 
liver disease progression and causing a systemic inflammatory response. Persistent 
stimulation of circulating immune cells increases plasma pro-inflammatory cytokines 
including IL-6, TNF-a and NO (32,33). Several of these molecules, namely TNF-a, 
can disrupt intestinal tight junctions augmenting gut leakiness. During 
decompensated cirrhosis, a further increase in intestinal permeability could contribute 
to enhanced translocation of PAMPs and viable bacteria (29) possibly leading to 
overt infections. As antibiotic intestinal decontamination normalizes the number of 
activated immune cells and their production of pro-inflammatory cytokines in 
experimental and human cirrhosis (34,35), the intestinal microbiota likely represents 
a driving force for systemic inflammation. Thus, recently it has been proposed that 
BT and systemic inflammation are the initial events leading to decompensation and 
organ failure in cirrhosis (36).Thus, the contribution of the gut microbiota to 
pathogenesis seems to become more pronounced with progressive disease and 
therefore represent an important therapeutic target in the management of cirrhosis and 
its complications, such as spontaneous bacterial peritonitis and hepatic 
encephalopathy (HE). 
 
Changes in Gut Microbiota in hepatic encephalopathy 
A firm scientific basis for a role for the gut microbiome in liver disease 
emerged in the middle of the last century with the recognition of the relationship 
between hepatic coma and the absorption of nitrogenous substances from the intestine 
(37). This was followed by the description of abundant coliforms in the small 
intestine of cirrhotic patients (38), and the role of bacteria was clinched by trials 
demonstrating that antibiotics led to clinical improvement in HE (39). 
The relevance of certain enteric organisms to the pathogenesis of HE is 
supported by studies indicating the efficacy of the poorly absorbed antibiotic with 
activity against enteric organisms, rifaximin, in overt (40) and subclinical HE (41). 
However, it is important to note that the precise nature of the changes in the 
composition and/or metabolic activity of the microbiota that generate these benefits 
remains to be determined. 
Molecular techniques, such as those based on sequence divergences of the small 
subunit ribosomal ribonucleic acid (16S rRNA) of bacteria (42) are now being 
directed at the more detailed investigation of the microbiota in liver disease. Recently 
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Zhang et al and Bajaj et al conducted studies in which they used a novel multitag 
pyrosequencing technique to characterize the microbiome from the fecal and colonic 
mucosal samples in patients with cirrhosis with and without HE and healthy controls 
(43,44,45).  Zhang et al found over-representation of two bacterial families, 
Streptococcaceae and Veillonellaceae, in cirrhotic patients with and without MHE as 
compared with controls (45). They also showed that gut urease containing bacteria 
Streptococcus salivarius was absent in controls but was present in cirrhotics with or 
without MHE. The abundance of S. salivarius was significantly higher in MHE than 
non-MHE patients, and its count positively correlated with ammonia levels in 
patients with MHE (45). Bajaj and coworkers performed cognition testing, and 
inflammatory cytokines and endotoxin analysis in cirrhotics with and without HE 
(43). They found altered fecal flora (higher Veillonellaceae), poor cognition, 
endotoxemia, and inflammation in patients with HE when compared with those 
without HE. However, there were no significant differences in the other microbiome 
families between HE and no HE groups. This study, for the first time, also 
demonstrated a direct positive correlation between Porphyromonadaceae and 
Alcaligeneceae and poor cognitive function in cirrhotics. Alcaligeneceae degrade 
urea to produce ammonia, which likely explains the association of Alcaligeneceae 
with poor cognitive function. They also demonstrated that Enterobacteriaceae, 
Fusobacteriaceae, and Veillonellaceae were positively, and Ruminococcaceae 
negatively, related to inflammation. Network analysis comparison showed robust 
correlations, only in the HE group, between the microbiome, cognition and 























3.2 COVERT HEPATIC ENCEPHALOPATHY 
 
3.2.1 Definition 
Mild HE that does not produce disorienting in time/space/identity or asterixis is 
called covert HE (2). This condition can be subdivided in an entirely asymptomatic 
condition, which is called minimal HE (MHE) and in a condition in which trivial 
signs of abnormality in attention or behaviour can be detected by trained medical 
staff or caregivers. This latter condition corresponds to stage I HE, according to West 
Haven classification (46). 
Covert HE (CHE) occurs in 20%–80% of patients with cirrhosis (47,48,49). 
 
3.2.2 Diagnosis  
Testing for MHE and CHE is important because it can prognosticate OHE 
development, indicate poor quality of life and reduced socioeconomic potential, and 
help counsel patients and caregivers about the disease. The occurrence of MHE and 
CHE in patients with chronic liver disease seems to be as high as 50%, so, ideally, 
every patient at risk should be tested. However, this strategy may be costly, and the 
consequences of the screening procedure are not always clear and treatment is not 
always recommended. An operational approach may be to test patients who have 
problems with their quality of life or in whom there are complaints from the patients 
and their relatives (50). Tests positive for MHE or CHE before stopping HE drug 
therapy will identify patients at risk for recurrent HE. Furthermore, none of the 
available tests are specific for the condition (51), and it is important to test only 
patients who do not have confounding factors, such as neuropsychiatric disorders, 
psychoactive medication, or current alcohol use. 
 
Testing strategies can be divided into two major types: psychometric and 
neurophysiological (52,53). Because the condition affects several components of 
cognitive functioning, which may not be impaired to the same degree, the 
International Society of Hepatic Encephalopathy (ISHEN) suggests the use of at least 
two tests, depending on the local population norms and availability, and preferably 
with one of the tests being more widely accepted so as to serve as a comparator. A 
listing of the most established testing strategies is given below. The test 
recommendation varies depending on the logistics, availability of tests, local norms, 
and cost (53). 
 
1) Portosystemic encephalopathy (PSE) syndrome test. This test battery consists of 
five paper-pencil tests that evaluate cognitive and psychomotor processing speed and 
visuomotor coordination. The tests are relatively easy to administer and have good 
external validity (51). The test is often referred to as the Psychometric Hepatic 
Encephalopathy Score (PHES), with the latter being the sum score from all subtests 
of the battery. It can be obtained from Hannover Medical School (Hannover, 
Germany), which holds the copyright (Weissenborn.karin@mh-hannover.de). The 
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test was developed in Germany and has been translated for use in many other 
countries. For illiterate patients, the figure connection test has been used as a subtest 
instead of the number connection test. 
2) The Critical Flicker Frequency (CFF) test is a psycho-physiological tool defined 
as the frequency at which a fused light (presented from 60 Hz downward) appears to 
be flickering to the observer. Studies have shown its reduction with worsening 
cognition and improvement after therapy. The CFF test requires several trials, intact 
binocular vision, absence of red-green blindness, and specialized equipment (48,54). 
3) The Continuous Reaction Time (CRT) test. The CRT test relies on repeated 
registration of the motor reaction time (pressing a button) to auditory stimuli (through 
headphones). The most important test result is the CRT index, which measures the 
stability of the reaction times. The test result can differentiate between organic and 
metabolic, brain impairment and is not influenced by the patient’s age or gender, and 
there is no learning or tiring effect. Simple software and hardware are required (55). 
4) The Inhibitory Control Test (ICT) is a computerized test of response inhibition 
and working memory (56) and is freely downloadable at www.hecme.tv. The ICT test 
has been judged to have good validity, but requires highly functional patients. The 
norms for the test have to be elaborated beyond the few centers that have used it. 
5) The Stroop test evaluates psychomotor speed and cognitive flexibility by the 
interference between recognition reaction time to a colored field and a written color 
name. Recently, mobile application software (‘‘apps’’ for a smartphone or tablet 
computer) based on the test has been shown to identify cognitive dysfunction in 
cirrhosis compared to paper-pencil tests (57). Further studies are under way to 
evaluate its potential for screening for MHE and CHE. 
6) The SCAN Test is a computerized test that measures speed and accuracy to 
perform a digit recognition memory task of increasing complexity. The SCAN Test 
has been shown to be of prognostic value (58). 
7) Electroencephalography examination can detect changes in cortical cerebral 
activity across the spectrum of HE without patient cooperation or risk of a learning 
effect (52). However, it is nonspecific and may be influenced by accompanying 
metabolic disturbances, such as hyponatremia as well as drugs. Possibly, the 
reliability of EEG analysis can increase with quantitative analysis. This specifically 
should include the background frequency with mean dominant frequency or spectral 
band analysis. Also, in most situations, EEG requires an institutional setup and 
neurological expertise in evaluation, and the cost varies among hospitals. 
 
Although the above-described tests have been used to test for MHE and CHE, 
there is, most often, a poor correlation between them because HE is a 
multidimensional dysfunction (59). Learning effect is often observed with 
psychometric tests and it is unclear whether current HE therapy plays a role in the test 
performance. Therefore, interpretation of these tests and consideration of the results 
for further management need an understanding of the patient’s history, current 
therapy, and effect on the patient’s daily activities, if signs of HE are found. 
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3.2.3 Role of confounders in the diagnosis 
Chronic alcohol misuse and HCV infection may act as confounders in the 
neuropsychological assessment for MHE, as they might directly impair brain 
functioning regardless of the liver disease they have caused (60,61). It is well known 
that chronic alcohol misuse is associated with specific changes in brain structure and 
function, which remain detectable long after patients have stopped drinking (62). The 
brain areas which are most susceptible to alcohol-related damage are the frontal 
lobes, periventricular structures and the cerebellum (63). The corresponding, 
damaged functions are executive function, working memory, strategy, switching, 
attention and psychomotor speed. Alcohol-related cirrhosis seems to be associated 
with more severe cognitive dysfunction compared to non-alcoholic cirrhosis based on 
some studies. The hypothesis that alcohol may have additional detrimental effect on 
the brain is supported by the more pronounced brain atrophy observed in patients 
with alcoholic cirrhosis compared to those with cirrhosis of different origin (64). 
Another potential confounder in the assessment of MHE is HCV infection. HCV 
infection has been found to be associated with fatigue, deficits in working memory 
and executive function (64). It has been hypothesized that these symptoms are caused 
by HCV colonization of microglia and/or interleukin activation (65). Forty-nine per 
cent prevalence of altered neuropsychological tests in patients with chronic HCV 
hepatitis has been reported (66); in contrast, Cordoba et al. (67) did not observe 
neuropsychological impairment in HCV-infected patients compared with patients 
with liver disease of other origin. 
 
3.2.4 Role of liver transplantation  
Generally, liver transplantation (LT) is thought to resolve cognitive deficits due to 
HE, but both new neurological diseases and an incomplete reversal of preexisting 
dysfunction can occur. It has been suggested that cognitive dysfunction after LT 
could be related to prior HE, anoxic/ischemic brain damage during surgery, osmotic 
myelinolysis, immunosuppressant toxicity, liver disease recurrence, comorbidities, 
and other metabolic alterations (68). Several studies have demonstrated substantial 
improvements in neuropsychological tests (69,70) and quality of life (71) after LT. 
Other studies have demonstrated improvements in cerebral function after LT with 
proton magnetic resonance imaging spectroscopy (72), positron emission tomography 
(73), and electroencephalograms (EEGs). Neuroimaging studies also support these 
findings (74). However, a number of studies have documented the persistence of 
various cognitive deficits within the months after LT (75,76). Only a few studies have 
analyzed the relationship between neuropsychological alterations and relevant 
presurgical variables to identify factors that place LT recipients at higher risk for 
cognitive dysfunction. Sotil et al. showed that transplant patients with a history of HE 
had worse neuropsychological performance as measured by the psychometric HE 
score and a lower critical flicker frequency in comparison with patients without a 




3.3 TREATMENT of HEPATIC ENCEPHALOPATHY 
 
3.3.1 General principles 
At this time, only OHE is routinely treated (11). Despite its subtle nature, MHE 
and CHE can have a significant effect on a patient’s daily living. Special 
circumstances can prevail where there may be an indication to treat such a patient 
(e.g., impairment in driving skills, work performance, quality of life, or cognitive 
complaints).  
The first step in treatment of HE is identifying and treating precipitating causes 
which includes management of hypovolemia, gastrointestinal bleeding, infection, 
excessive diuretic use, diarrhea, vomiting, hyponatremia, hypokalemia or 
hyperkalemia, constipation, benzodiazepine use and noncompliance with lactulose or 
rifaximin therapy (77).  
Current therapies for HE are based on ammonia-lowering with the hypothesis 
that the colon is the primary organ that generates ammonia. Most drugs have not been 
tested by rigorous randomized, controlled studies and are utilized based on 
circumstantial observations (2). These agents include nonabsorbable disaccharides, 
such as lactulose, and antibiotics, such as rifaximin. Other therapies, such as oral 
branched-chain amino acids (BCAAs), intravenous (IV) L-ornithine L-aspartate 
(LOLA), probiotics, and other antibiotics, have also been used. 
 
3.3.2 Treatment of overt hepatic encephalopathy 
Complex pathophysiology and limited understanding of HE at present has led 
to limited therapy for the management of HE (78). Although the evidence for 
ammonia is robust, the synergistic role of inflammation and infection in modulating 
the cerebral effects of ammonia has been shown to be important. The most commonly 
utilized pharmacological agents still include the non-absorbable disaccharides 
lactulose and lactitol. Recent literature has supported the role of lactulose in both 
primary, secondary and treatment of covert and overt HE. Although antimicrobial 
agents such rifaximin have had an established role in the treatment of encephalopathy 
recent metaanalysis has shown efficacy of lactulose similar to antimicrobials. 
However studies enrolled in most of these metanalysis are of poor quality that may 
have affect the overall results of these metanalysis. Recently combining the rifaximin 
and lactulose has shown promising results in the treatment of overt HE which needs 
further validation in multicenter trials (78). Till we have more definitive agents non-




Disaccharides (lactulose and lactitol) get metabolized by the bacteria in the 
colon to acetic and lactic acid. This acidification of the colon not only creates a 
hostile environment for the survival of intestinal bacteria with urease activity 
involved in the production of ammonia in the gut, but also facilitates the conversion 
of NH3 to non-absorbable NH4+. Both effects result in reduced levels of ammonia in 
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the colon and portal blood. Nonabsorbable disaccharides also cause a 4-fold increase 
in faecal nitrogen excretion due to their cathartic effect (79). The non-absorbable 
disaccharides have been a mainstay of therapy for HE for decades, and have been 
extensively studied in several small clinical trials. Oral lactulose was used in majority 
of these studies though some had used lactitol and lactulose enemas also (80,81). 
Lactulose is the most commonly utilized nonabsorbable disaccharide for HE and it is 
generally used as initial treatment for OHE. Similarly lactitol is a disaccharide analog 
of lactulose which is neither absorbed nor broken down in the small intestine. A large 
meta-analysis of trial data did not completely support lactulose as a therapeutic agent 
for treatment of OHE, but for technical reasons, it did not include the largest trials, 
and these agents continue to be used widely (82). Though it is assumed that the 
prebiotic effects (the drug being a nondigestible substance that promotes the growth 
of beneficial microorganisms in the intestines) and acidifying nature of lactulose have 
an additional benefit beyond the laxative effect, culture-independent studies have not 
borne those out (83,84). In addition, most recent trials on lactulose have been open 
label in nature. Cost considerations alone add to the argument in support of lactulose 
(85). In some centers, lactitol is preferred to lactulose, based on small meta-analyses 
of even smaller trials (86,87). The dosing of lactulose should be initiated with 25 mL 
of lactulose syrup every 12 h until at least two soft or loose bowel movements per 
day are produced. Subsequently, the dosing is titrated to maintain two to three bowel 
movements per day. This dose reduction should be implemented. It is a 
misconception that lack of effect of smaller amounts of lactulose is remedied by 
much larger doses. There is a danger for overuse of lactulose leading to 
complications, such as aspiration, dehydration, hypernatremia, and severe perianal 
skin irritation, and overuse can even precipitate HE (88). 
 
Rifaximin  
Rifaximin is a nonsystemic antibiotic with a broad spectrum of antibacterial 
action covering Gram-positive and Gram-negative organisms, both aerobes and 
anaerobes, and it is structurally similar to Rifampin. By binding to bacterial DNA-
dependent RNA polymerase, rifaximin inhibits bacterial RNA/protein synthesis. 
Structurally, the benzimidazole ring limits systemic absorption to 0.4%, with the 
primary mode of excretion via feces and low levels of drug excreted in urine or bile. 
Being virtually non-absorbed, its bioavailability within the GI tract is rather high with 
intraluminal and fecal drug concentrations that largely exceed the minimal inhibitory 
concentration values observed in vitro against a wide range of pathogenic organisms. 
Due to its low rate of systemic absorption, rifaximin appears to be relatively safe. 
 
Rifaximin has been used for the therapy of HE in a number of trials (89) comparing it 
with placebo, other antibiotics, nonabsorbable disaccharides, and in dose-ranging 
studies. These trials showed effect of rifaximin that was equivalent or superior to the 
compared agents with good tolerability. Long-term cyclical therapy over 3–6 months 
with rifaximin for patients with OHE has also been studied in three trials (two 
compared to nonabsorbable disaccharides and one against neomycin) showing 
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equivalence in cognitive improvement and ammonia lowering. A multinational study 
(40) with patients having two earlier OHE bouts to maintain remission showed the 
superiority of rifaximin vs. placebo (in the background of 91% lactulose use). No 
solid data support the use of rifaximin alone. 
 
3.3.3 Treatment of covert hepatic encephalopathy 
Once patients with cirrhosis develop MHE, they are at a substantial risk of 
progression to OHE, resulting in a significant burden to the healthcare system and an 
increased risk of mortality (8;90). Studies have consistently shown that patients with 
MHE have a diminished quality of life, cognitive function, daily function, and driving 
impairment (47;91). Moreover, it has been demonstrated that even after therapy and 
improvement to normal mental status, a single episode of OHE may continue to have 
residual negative effectson cognitive function (92). Therefore, it would only seem 
logical to consider prophylactic treatment for HE in patients with cirrhosis. 
Currently, there is a paucity of data regarding the role of prophylaxis in CHE. 
Although it is not standard to offer therapy for MHE and CHE, studies have been 
performed using several modes of therapy. The majorities of studies have been for 
less than 6 months and do not reflect the overall course of the condition. Trials span 
the gamut from small open-label trials to larger, randomized, controlled studies using 
treatments varying from probiotics, lactulose, and rifaximin. Most studies have 
shown an improvement in the underlying cognitive status, but the mode of diagnosis 
has varied considerably among studies. A minority of studies used clinically relevant 
endpoints. It was shown, in an open-label study (93), that lactulose can prevent 
development of the first episode of OHE, but the study needs to be replicated in a 
larger study in a blinded fashion before firm recommendations can be made. Studies 
using lactulose and rifaximin have shown improvement in quality of life (94,95) and 
also in driving simulator performance (96). Probiotics have also been used, but the 
open-label nature, varying amounts and types of organisms, and different outcomes 
make them difficult to recommend as therapeutic options at this time (97,98,99). 
Because of the multiple methods used to define MHE and CHE, varying endpoints, 
short-term treatment trials, and differing agents used in trials to date, routine 
treatment for MHE is not recommended at this stage. Exceptions could be made on a 
case-by-case basis using treatments that are approved for OHE, particularly for 
patients with CHE and West Haven Grade I HE. 
 
 
3.3.4 Modulation of gut microbiota improves HE  
Gut microbiota is clearly implicated in the development of HE, thus its 
modulation by various agents provides an opportunity to treat covert and overt HE. 
Successful modulation of gut microbiota leading to improvement in HE strengthens 
the belief that derangement in microbiota is certainly an important factor in 
development of HE. 
Recent studies, which utilized multitag pyrosequencing technique to 
characterize the microbiome from the fecal and colonic mucosal samples in patients 
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with cirrhosis, suggested that probiotics, lactulose and gut specific antibiotic like 
rifaximin cause improvement in dysbiosis and HE. Such improvement relates to both 
changes in microbiota-associated metabolic function and improvement in dysbiosis. 
 
Lactulose  
Lactulose is used as standard therapy in HE. Traditionally, lactulose/lactitol has 
been the standard to which newer therapies have had to be compared. Its use was 
prompted by studies suggesting that colonic bacteria are the main ammonia producers 
in the body (100). 
The mechanism of action through which disaccharides works is multifaceted. 
While intestinal “hurry” is their best-known mechanism for eliminating fecal waste 
products, including ammonia, DS are much more than simple cathartics. Upon 
entering the colon, DS are cleaved into monosaccharides by the bacterial flora, some 
of which (eg, Lactobacilli and Bifidobacteria) can then incorporate these 
monosaccharides into subsequent generations of bacteria, thereby gaining a growth 
advantage. The unincorporated monosaccharides are also utilized as fuel for the 
bacteria. This fermentation process generates lactic acid and hydrogen ions, thereby 
acidifying the fecal stream within the colon and causing subsequent protonation of 
ammonia molecules (NH3) into ammonium ions (NH4+). Because the charged NH4+ is 
poorly absorbed across the colonocyte, the ion remains trapped within the colonic 
lumen. In addition, this protonation reaction can allow for movement of NH3 from the 
bloodstream back into the colonic lumen in a classic example of stoichiometry (NH3 
+ H+➝ NH4+). Another mechanism of action that has been postulated for DS involves 
transformation of the fecal flora: reduction of urease-producing bacteria (which are 
not given a growth advantage with DS) in favor of the proteolytic species (eg, 
Lactobacilli and Bifidobacteria). In this regard, disaccharides can be considered a 
prebiotic—ie, a “meal” for the bacterial biomass. 
In healthy individuals, lactulose therapy does not significantly change 
microbial composition using culture-independent techniques (101). In patients with 
cirrhosis, Bajaj et al demonstrated that, despite lactulose treatment in those patients 
who developed HE, there was an increase in dysbiosis, with a lower CDR and 
relative abundance of gram negative non-autochthonous bacteria (Enterobacteriaceae, 
Bacteroidaceae) (44). This is in contrast to earlier culture-based studies which 
showed increased autochthonous bacteria (Lactobacillaceae) after administration of 
lactulose in patients with cirrhosis (84). Lactulose withdrawal did not exert a very 
significant effect on the composition of the fecal microbiome except for the reduction 
of Faecalibacterium species, suggesting that changes in gut bacterial function rather 
than a change in the microbiome composition may be responsible for the effects of 
lactulose. In another study HE patients underwent characterization of their phenotype 
(cognition, inflammatory cytokines, in vivo brain MR spectroscopy), gut microbiome 
and urine and serum metabolome analysis while on lactulose and on days 2, 14 and 
30 post-withdrawal. When patients with and without recurrent HE post-withdrawal 
were compared, brain MRS findings consistent with low grade brain edema 
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(increased glutamine/glutamate and decreased myo-inositol) were reported, with a 
relatively minor change in fecal microbiome (reduction in abundance of stool 
Faecalibacterium sp). HE recurrence was associated with altered choline metabolism 
by gut microbiome, resulting in low urine tri-methylamine oxide, high urine glycine 
and high serum choline, dimethylglycine, creatinine, which play an important role in 
development of HE (83). 
 
Rifaximin 
Rifaximin, a nonsystemic antibiotic with a broad spectrum of antibacterial 
action covering Gram-positive and Gram-negative organisms, is presumed to 
modulate intestinal bacteria, thereby reducing intestinal ammonia and toxin formation 
(102).  
The effect of rifaximin therapy on the metabiome, i.e. the interaction between 
the phenome (cognition, liver disease severity and endotoxin level), microbiome and 
metabolome, was evaluated in patients with cirrhosis and MHE. There was no 
significant microbial change after treatment with rifaximin, apart from a modest 
decrease in Veillonellaceae and increase in Eubacteriaceae. A significant 
improvement in cognition, reduction in endotoxemia and a significant increase in 
serum long-chain fatty acids were seen after rifaximin therapy. A significant linkage 
of pathogenic bacterial taxa was demonstrated with the metabolites, especially those 
linked to ammonia, aromatic amino acids and oxidative stress, which shifted from a 
positive correlation to a negative correlation after rifaximin therapy, reflecting 
changes in bacterial metabolic function. These results suggest that the mechanism of 
action of rifaximin that lead to cognitive improvement could be associated with 
changing microbiota-associated metabolic function rather than just changing the 
numbers of beneficial or harmful bacteria (103). 
 
Probiotics  
Probiotics are live microorganism that, when admistered in adequate amounts, 
confer a health benefit on the host (104). Examples include strains of the genera 
Bifidobacterium and Lactobacillus.  
Liu et al. for the first time demonstrated that cirrhotic patients with MHE had 
substantial derangements in the gut microbiota, with significant fecal overgrowth of 
potentially pathogenic Escherichia coli and Staphylococcal spp. Synbiotic treatment 
significantly increased the fecal content of non-urease—producing Lactobacillus 
species at the expense of these other bacterial species. Such modulation of gut 
microbiota was associated with a significant reduction in blood ammonia levels, 
endotoxemia and reversal of MHE in half of patients. The Child–Turcotte–Pugh 
functional class improved in nearly half of patients. This study demonstrated that 
treatment with synbiotics could be an alternative to lactulose for management of 
MHE in patients with cirrhosis. In this study, culture-based techniques were used for 
the characterization of gut microbiota (105). 
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Another recent study have demonstrated that over a 6-month period, treatment 
with probiotic VSL#3 significantly reduced the risk of hospitalization due to HE and 
significantly reduced Child-Pugh and MELD scores. Treatment with probiotic was 
also associated with improvements in rates of SIRS and plasma indole (106). 
Despite a number of trials showing the efficacy of probiotics and synbiotics, 
their role in the management of HE is inconclusive and, currently, they cannot be 







































4. STUDY AIMS 
 
1) Screening for Covert Hepatic Encephalopathy in routine clinical practice is a 
relevant issue. While significant progress has been made in understanding the 
importance of CHE, to date there is no standardized algorithm for diagnosis. There 
are, also, no consensus guidelines regarding screening for CHE and there is debate as 
to the utility of testing all cirrhotic patients as opposed to a limited testing strategy for 
those patients with evidence of cognitive impairment. The recent published HE 
guidelines suggest that, ideally, every patient at risk for CHE should be tested (2). 
Tools useful at this aim are the Psychometric Hepatic Encephalopathy Score (51), 
quantified EEG (107), (Critical Flicker Frequency (CCF) (54) or computerized tests 
(58,56). All these well recognized techniques, although more or less sensitive and 
objective, require some kind of equipment, even if this may be a simple pencil and a 
form of paper to be filled in. However, it is well known and accepted that some kind 
of evaluation of mental function can be obtained also by simple verbal questions, 
such as those concerning orientation in time/space/identity that are used to detect 
overt HE, which have obvious intercultural applicability and can be easily used in 
clinical practice. Therefore, this study focused on the applicability of a simple verbal 
psychometric test to assess routinely patients with cirrhosis who do not have overt 
HE. The Animal Naming Test (ANT), which is a semantic fluency test, seemed to 
have potential for this aim. The rationale of the choice of the ANT is that the 
knowledge of animal names is reasonably widely spread in humans of every culture, 
and might be only slightly influenced by age or education. Thus, the first aim of this 
study was to test the ANT in the detection of covert HE. Secondary aims were to: I) 
standardize the ANT in a sample of healthy subjects, II) produce a scoring system to 
assess the risk of CHE, and III) assess the prognostic value of ANT. 
 
2) It can be difficult to differentiate between the effects of CHE and those resulting 
from other causes. For example, psychometric tests are able to detect functional 
deficits, but are unable to differentiate between different causes for these deficits. 
Therefore, the diagnosis of CHE should consider other factors which can cause 
cognitive impairment by itself and act as confounders. Recent studies show that 
chronic alcohol misuse, HCV infection and cirrhosis per se may cause cognitive 
alterations. Thus, the second aim of the present study was to assess the influence of 
alcohol misuse, HCV infection and cirrhosis per se on the neuropsychological and 
EEG profile and to evaluate the role of alcohol misuse, HCV infections as potential 
confounding factors in the detection of CHE-MHE. Parallel aims were evaluate also 
the role of diabetes, aging and a low level of educations as potential confounding 
factors.  
 
3) The influence of liver transplantation on mental performance is debated, as is the 
role of pretransplant overt hepatic encephalopathy. It seems important to identify 
CHE in patients awaiting liver transplantation for the proper interpretation of 
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disorders occurring after transplantation. Recent data from studies evaluating liver 
transplantation suggest that the associated cognitive changes may not be totally 
reversible. Assuming that residual cognitive deficits after liver transplantation may 
reflect the extent of pretransplant morbidity, the third aim of this study was to 
evaluate the time course of the neuropsychological and EEG features of patients with 
cirrhosis before and after liver transplantation with respect to prior episodes of OHE. 
 
4) Gut microorganisms may play a fundamental role in the pathogenesis and 
worsening of liver disease and pathology, where alteration of their composition and 
the production of toxic compounds may be considered as trigger actors. In particular, 
gut ammonia production by microbial activity is one of the main factors implicated in 
HE. Ammonia reducing strategies target mainly gut microbiota, by administration of 
prebiotics (lactulose), antibiotics (rifaximin) and probiotics (VSL#3). Although the 
role of ammonia in the pathophysiology of HE is well established, the factors 
governing its productions by the gut microbiota are poorly understood.  
The forth aim of this study was to investigate how gut microbiota modulation 
by prebiotics, antibiotics and probiotic treatments affected microbial ammonia 
production and the relative abundance of important members of the gut bacteria, 
within the cirrhotic environment. 
 
In summary, the aims of the present study were the follows:  
1) test a verbal psychometric test, the Animal Naming Test, for the detection of CHE 
2) estimate the role of alcohol misuse, HCV infection, aging, diabetes and a low level 
of education as potential confounding factors in the detection of CHE-MHE   
3) evaluate the time course of the neuropsychological and EEG features of patients 
with cirrhosis before and after liver transplantation with respect to prior episodes of 
OHE, assuming that residual cognitive deficits after LT may reflect the extent of 
pretransplant morbidity 
4) investigate how the use of lactulose, rifaximin or VSL#3 affects gut microbial 

















5. PATIENTS AND METHODS 
 
5.1 Aim 1: Animal Naming Test for detection of covert hepatic encephalopathy 
  
Three samples of subjects underwent the ANT (see below). The first one was 
composed by healthy Italian individuals and served to standardize the ANT, the 
second one by a consecutive sample of patients with cirrhosis who were enrolled 
either in the University Hospital of Padua or Rome, the third one by a consecutive 
sample of patients with inflammatory bowel disease (IBD) enrolled in the University 
Hospital of Padua. 
 ANT standardization sample. A convenience sample of 208 healthy volunteers 
(42% males) enrolled in general population after a structured interview to exclude 
alcohol misuse, consumption of psychotropic drugs, insulin-dependent diabetes or 
diseases that can damage cognitive functions. The sample was stratified according to 
age in order to have participants for each of the following age classes: 18-40, 41-60, 
61–70, 71-80, >80 years. Four educational levels were considered: at least 5; at least 
8; at least 13 years; and university degree (≥ 17 years). Following informed consent, 
each individual underwent the ANT both at 1 (ANT1) and 2 minutes (ANT2). 
Control sample of hospitalized subjects with IBD. A group of 11 in-patients 
with IBD without liver disease -having the same exclusion criteria considered for the 
patients with cirrhosis- was enrolled, as a control group of hospitalized individuals 
with a chronic disease. Their age was 47±15 years (males 55%; educational level: at 
least 5 years 18%, at least 8 years 18%, at least 13 years 55%, university degree 9%).  
 
Patients sample 
Patients with cirrhosis. The patient population was recruited in two University 
hospital centers (Padua and Rome, Italy). It comprised 327 consecutive patients (69% 
males) with cirrhosis (172 from Padua, 155 from Rome; age 60 ± 13 years, mean ± 
SD; Child A: 40%, B: 37%, C: 23%). Their clinical and biochemical findings are 
shown in Table 2. Subjects were considered eligible if they had cirrhosis with or 
without clinical signs of HE. Exclusion criteria were age<18 yrs, neurological 
comorbidities (e.g. prior cerebrovascular disease and dementia), psychiatric 
disorders, alcohol misuse in the previous 6 months or use of sedatives (e.g. 
benzodiazepines, neuroleptic, antiepileptic and opiate drugs), heart, respiratory or 
renal failure that could confound the assessment of the mental state.  
A subgroup of 202 patients with cirrhosis (153 from Rome and 49 from Padua) 
was available to be followed up. The patients were followed up for up one year. Both 
the first breakthrough of OHE and survival were considered. The patients who 
underwent liver transplantation in the follow up were censored on the day of 
transplant. The follow up for the first breakthrough of OHE was 216 (70-365) days 
(median and interquartile range); the follow up for survival was 328 (128-365) days. 





Table 2. Demographic, clinical and biochemical data of patients with cirrhosis and 
demographic data of healthy subjects  
Healthy controls n=208 
Age a (years) 54 ± 19 
Males/females  87 (42%)/121 (58%) 
Age classes: 
   18-40 years 
   41-60 years 
   61-70 years 
   71-80 years 
   >80 years 
 
60 (29%)                 
60 (29%)                  
38 (18%)                    
28 (13%) 
22 (11%)                     
Education levels 
   At least 5 years 
   At least 8 years 
   At least 13 years 
   University degree (≥17 years) 
 
59 (28%), mean age±SD 66±2 
79 (38%), mean age±SD 49±2 
39 (19%), mean age±SD 49±3 
31 (15%), mean age±SD 49±3 
Patients with cirrhosis n=327 
Age a (years) 60 ± 13 years                         MELD score                             13 ± 6 
Males 226 (69%)                              Previous episodes of OHE        116 (35%) 
Education levels 
     At least 5 years 
     At least 8 years 
    At least 13 years 
    University degree (≥17 years) 
                                                Ascites rating  
34%                                                    None                             59% 
37%                                                    Mild/Moderate             29% 
21%                                                    Severe                          12% 
8%                                     
Etiology of cirrhosis 
    HCV-related 
    Alcoholic 
    Mixed 
    Others  
                                                 Albumin (g/L)                         35 ± 6.5 
61%                                          Bilirubin tot.(mg/dl)               3.4 ± 6.1 
26%                                          INR                                         1.4 ± 0.34 
7%                                            Prothrombin time (%)             57 ± 21 
6%                                            Creatinine (mg/dl)                0.99 ± 0.8 
Child-Pugh class  
   A 
   B 
   C 




Abbreviations: MELD (Model for End Stage Liver Disease); OHE, overt hepatic encephalopathy 
a (mean±SD); b 1st: at least 5 years; 2nd: at least 8 years; 3rd : at least 13 years; 4th: university degree (≥17 years): c The grade of HE was determined 
according to the West Haven Criteria  
 
Measures  
 The ANT: in a quiet room without distractions, the subjects were asked to list 
as many animals they could. All repetitions and errors were excluded from the 
calculations. The animals listed in 1 minute (ANT1) were considered for patients and 
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healthy controls. In the latter for completeness of the standardization process, also the 
animals reported in 2 minutes (ANT2) were calculated.   
Clinical assessment of HE. The patients were examined by clinicians with high 
expertise in HE assessment. The assessment included full neurological examination, 
in particular to detect asterixis and grading of the neuropsychiatric abnormalities 
according to the West Haven criteria (46), using operative criteria (2). All patients 
without OHE underwent the PHES battery that was scored by the age and education-
adjusted Italian norms (108). Patients were qualified as unimpaired (clinically 
normal, PHES normal), or as having CHE (MHE or grade I HE according to West 
Haven classification) or OHE (disoriented or presence of asterixis).  
Neurophysiological assessment of HE. 146 patients from the Padua centre 
underwent also the digital EEG and 95 patients the CFF. Spontaneous closed-eyes 
resting EEG activity was recorded by digital EEG equipment (Brainquick 3200, 
Micromed, Italy) in the morning. A standard 21-channel cap (Micromed, Italy) was 
used, and the electrodes placed according to the 10–20 International System (109). 
The EEG tracing was assessed by spectral analysis after visual inspection to exclude 
artefacts. Spectral analysis was carried out on the derivation P3-P4 in the frequency 
range of 1–25.5 Hz. The EEG alterations were classified into three grades according 
to mean dominant frequency MDF (i.e. the mean frequency weighted by the power of 
each frequency band) and to the relative power of the theta and delta bands as 
follows: grade 1 – MDF > 6.8 Hz and theta relative power ≥ 35% –, grade 2 – MDF ≤ 
6.8 Hz and delta relative power < 49% –, grade 3 – MDF ≤ 6.8 Hz and delta relative 
power ≥ 49%, as previously described (110). The CFF was measured by a portable, 
battery-powered analyzer (Hepatonorm Analyzer; R&R Medi Business Freiburg 
GmbH, Freiburg, Germany). The analyzer evokes an intrafoveal light stimulus with 
defined pulses of light at a wavelength of 650 nm, luminance of 270 cd/m2, and 
luminous intensity of 5.3 mcd. The frequency of the red light, which is initially 
generated as a high-frequency pulse (60 Hz) and which gives the patient the 
impression of a steady light, was reduced gradually until the patient had the 
impression that the steady light had changed to a flicker. The patient registers this 
change by pressing a hand-held switch. After a practice run, the test was repeated five 
times and an average value obtained; this was qualified as abnormal if <39 Hz (54). 
 
Statistical analysis 
In healthy sample, analysis of covariance (ANCOVA) was used to evaluate if 
age, level of education and gender were predictors of the ANT and to evaluate the 
effect of education levels and age classes on the ANT. The Newman-Keuls test was 
used for post hoc comparisons. The thresholds of normality for the ANT1 and ANT2 
in healthy subjects were fixed at the 2.5th percentile. In patients with cirrhosis, 
general linear model was used to evaluate if a history of OHE (dichotomous variable 
‘yes’ or ‘no’) and alcohol etiology (dichotomous variable ‘yes’ or ‘no’) were 
predictors of ANT1, adjusting for age (in years) and education (years of education). 
Receiver operating characteristic (ROC) curves analysis and the Youden test was 
27 
 
performed to determine the best threshold for the ANT1. The sensitivity, specificity, 
positive (PPV) and negative predictive values (NPV) for the detection of subjects 
with CHE vs. unimpaired by the ANT1 were calculated. The correlations between the 
ANT and the EEG and the CFF were assessed using Pearson r correlation. Survival 
analysis was performed by the Kaplan Mayer method and comparisons were 
performed by the Log-rank test or the χ2 test, when appropriate. Multivariate survival 
study was performed by the Cox model. Results are expressed as means ± SD, unless 
otherwise specified.  
 
5.2 Aim 2: Confounders in the detection of covert hepatic encephalopathy 
 
Patients 
One hundred and fifty patients were studied (males 68%; age 52 ± 9 years). 
They were retrospectively selected from a database of 1200 subjects studied in a 
tertiary referral centre for hepatic encephalopathy (HE) of the Department of 
Medicine of Padova University Hospital, Italy. The selection was performed to obtain 
six groups of individuals matched for age and education and, as far as patients with 
cirrhosis were concerned, the severity of liver disease was assessed by the MELD 
score. Patients were selected consecutively until reaching 30 per group. In line with 
an exploratory study design, the number of 30 subjects per group was chosen 
arbitrarily. The following six groups were defined: (i) 30 non-cirrhotic patients with 
chronic HCV hepatitis, (ii) 30 noncirrhotic chronic alcohol misuser, (iii) 30 patients 
with HCV-related cirrhosis, (iv) 30 patients with alcohol related cirrhosis, (v) 30 
patients with cirrhosis without a history of alcohol consumption and without HCV 
infection, (vi) 30 healthy subjects without history of alcohol consumption and 
without HCV infection. This way, it was possible to compare the main groups 
alcohol/nonalcohol, cirrhosis/no cirrhosis, HCV/no HCV, of 1:1 or 1:2 and calculate 
the interactions between them. Of the patients with cirrhosis not related to alcohol or 
HCV infection: 18 had HBV-related cirrhosis, three had HBV–HDV-related 
cirrhosis, five had primary biliary cirrhosis, one had haemochromatosis, one had 
Budd–Chiari syndrome and two had cryptogenic cirrhosis. The diagnosis of cirrhosis 
was based on case history, clinical examination, biochemical and ultrasound findings 
and was confirmed by biopsy where needed. Specifically, the diagnosis of HCV-
related cirrhosis was based on positive anti-HCV-ELISA and fibrosis score ≥4 on 
liver biopsy, based on the Metavir classification (21). The diagnosis of HCV-related 
hepatitis without cirrhosis was based on positive anti-HCV-ELISA/HCV-RNA PCR 
and fibrosis <4 on liver biopsy. The absence of HCV hepatitis was assessed by 
antibodies test. The presence of chronic alcohol misuse was confirmed by quantity 
and frequency questionnaires, and only patients under the care of an alcohol specialist 
centre were considered. All patients with chronic alcohol misuse had a daily alcohol 
intake of more than 30 g/day in females and 60 g/day in males. Patients with alcohol-
related cirrhosis had been abstinent for more than 6 months, and the absence of 
alcohol consumption was declared by the patient and confirmed by a relative. The 
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groups were selected so that their demographical variables were matched (Table 3); 
in addition, patients with cirrhosis were also matched (MELD score) (Table 2). The 
exclusion criteria were the presence of significant neurological and psychiatric 
disease (mood or personality disorders), current OHE, use of psychoactive and 
antihypertensive medication.  
 
Table 3. Demographic variables of the six groups of subjects 
 
Cirrhotic groups 
                  HCV-cirrhosis          Alcohol-related cirrhosis             non alcohol/HCV cirrhosis      
                                                             
Age (years)  54 (±8)   52 (±8)    50 (±11) 
Education (years)       8 (±3)    8 (±3)    8 (±3) 
Males:females (n)   19:11   19:11    23:7 
 
   
Non cirrhotic groups 
  HCV hepatitis    Chronic alcohol abusers                Healthy subjects   
 
Age (years)  49 (±9)   53 (±9)    53 (±9) 
Education (years)    8 (±3)   8 (±4)    8 (±3) 




All patients underwent comprehensive neuropsychological examination by an 
experienced neuropsychologist. The following battery of psychometric tests was 
administered: (i) The Phonemic Verbal Fluency (PVF) is a verbal and executive 
function test, in which subjects are asked to generate as many words as possible, 
starting with a given letter (C, P, S) within a time span of one minute for each letter. 
(ii) The Trail Making Test A (TMT A) is a psychomotor speed test with visual search 
and attentional components, in which subjects are required to connect 25 numbered 
circles in sequential order, as quickly as possible. (iii) The Trail making test B (TMT 
B) is a psychomotor speed test with visual search and higher attentional components 
compared to TMT A, implicating divided attention and task switching, in which 
subjects are required to connect 25 circles containing numbers from 1 to 13 and 
letters from A to N in sequential and alternating order (1-A-2-B-3-C. . .), as quickly 
as possible; (iv) The Difference TMT B minus TMT A (or TMT (B-A) was obtained 
subtracting performance time of TMT A from performance time of TMT B. This 
provides an estimate of the exceeding time required to perform TMT B compared to 
TMT A, which is independent of the motor and search components of the task, which 
are comparable in TMT A and TMT B. Therefore, it is an estimate of the higher 
selection and attention abilities required to perform TMT B. (v) The Digit Span (DS) 
is a short-term memory test, in which the subject is required to repeat a list of 
numbers in increasing order. (vi) The Memory with Interference Task at 10 and 30 s 
(ITM 10 and ITM 30) is a working memory test, in which subjects are required to 
memorize three letters and to repeat them after they have been busy with an 
interfering task (counting two by two). (vi) The Immediate and Delayed Story Recall 
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Memory (ISRM and DSRM) is a memory tests, in which subjects are required to 
repeat a story immediately after it has been told, and then again after some 4 min. 
The diagnosis of MHE was defined by the presence of two abnormal psychometric 
tests (TMT A and TMT B) and/or abnormal slowing of the EEG (22). While the 
detection of MHE was based on two psychometric tests, a comprehensive 
neuropsychological battery was administered to fully characterize the 
neuropsychological profile of the patients, and thus to assess any possible form of 
cognitive impairment. The TMT A and the TMT B were performed using the forms 
and the reference values standardized in our Unit (23). For the other tests, Italian 
procedures and reference values were utilized (24). Ninety-five per cent of patients 
had not undergone previous psychometric testing and were administered one of the 
available versions of the tests, randomly chosen; the remaining 5% had psychometric 
testing over the previous 6 months and were given a different version compared to 
baseline. In this subgroup different versions of the tests were utilized. Test 
performance was expressed by age and education-adjusted Z values. In addition, the 
mean Z score of all psychometric tests (MZPT) was used as overall cognitive index. 
 
EEG assessment 
Both patients and healthy subjects underwent recording of spontaneous, wake, 
eyes-closed EEG activity, immediately after the psychometric evaluation, by using a 
21-electrode EEG cap (for the procedure’s description see above). 
 
Statistical analysis 
Results are expressed as mean ± SD. The distribution of data was analysed by 
Kolmogorov–Smirnov test: all psychometric tests and EEG parameters fitted a 
Gaussian distribution. All the neuropsychological tests were expressed as age and 
education-adjusted Z scores. In that way, psychometric tests were homogeneously 
expressed and comparable, so that the neuropsychological profiles could be analysed 
by repeated measure ANOVA. Two-way ANOVA was used to assess the influence of 
different factors on the neuropsychological profile. The Z score of 
neuropsychological tests was used as within condition and the aetiology of cirrhosis 
(three levels: alcohol, HCV, no alcohol/HCV) or the presence of cirrhosis (two 
levels: present vs. absent as between condition,) were used as between condition 
respectively. Two-way ANOVA using aetiology (two levels: alcohol vs. HCV) and 
cirrhosis (two levels: present vs. absent) was used to assess the effect on EEG 
spectral parameters. One-way ANCOVA was used to assess the role of aetiology 
within cirrhotic patients, adjusting for the severity of liver disease evaluated by the 
MELD score. Post hoc comparisons were carried out by the Tukey test.  
 
5.3 Aim 3: Reversibility of Cognitive Impairment after Liver Transplantation 
 
Patients 
The present study consisted of prospective assessment of neuropsychological 
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and neurophysiological function before and after LT. Out of consecutive 278 patients 
with liver cirrhosis evaluated in the tertiary referral centre for HE of the Padova 
University Hospital, 246 were placed in the waiting list for LT. Of these, 28 patients 
died on the waiting list and 91 patients were successfully transplanted. Of the latter, 
10 patients died during the first year after LT (6 within one month -  for sepsis, 2 in 
the period ranging between six and nine months, due to cardiovascular events). Nine 
patients were lost to follow-up and 7 patients were excluded (2 because of alcohol 
intake, 3 for relapse of liver disease and 2 for cerebrovascular events immediately 
after LT). 65 patients (54 males; age [mean ± SD] 51±8) were included.  
 Prior to LT, patients with severe renal failure, use of psychoactive drugs, free of 
alcohol intake less than 6 months, inability to participate in psychometric tests, overt 
or anamnestic neurological diseases (except HE), such as cerebrovascular events, 
dementia or Parkinson’s disease were excluded. After LT, patients were excluded if 
they showed recurrence of severe liver disease, alcohol misuse relapse, use of 
psychoactive drugs, cerebrovascular events, pontine myelinolysis and central nervous 
system infections. 
 To assess the role of previous HE on the post transplant cognitive profile the 
following variables were collected: number of OHE episodes, grade of HE based on 
the West Haven criteria. Model for End-Stage Liver Disease (MELD) scores were 
calculated at the time of neuropsychological and neurophysiological examination 
before LT. The indication for LT was end-stage liver disease in 52 patients and 
hepatocellular carcinoma in 13. Immunosuppressive therapy at the time of post-LT 
assessment was tacrolimus as monotherapy (n=34; dose 4±3 mg/die) or in association 
with mofetil mycophenolate (n=23; dose 1000 mg/die) or cyclosporine (n=8; dose 
180±47 mg/die). Patients who completed the post-LT evaluation had good liver (AST 
50.4 ± 78 UI/l; Bilirubin total 0.9 ± 0.5 mg/dl; Albumin 41.3 ± 7.3 mg/dl; 
Prothrombin time 82±16%) and renal function (creatinine 1.23 ± 0.35 mg/dl). 
 
Methods 
All patients underwent an extensive neuropsychological evaluation and an 
EEG spectral analysis 2-8 months prior to and 9-12 months after LT. Furthermore, in 
a subgroup of 11 patients the measures were also performed 3 and 6 months after LT 
to test the time course of the psychometric and EEG findings. The demographic and 















Table 4. Demographic, clinical and biochemical characteristics of the total sample of 
patients studied before liver trasplantation (n=65), and according to the presence of 
previous episodes of OHE.  
 
 Total sample  
n=65 
Prior OHE  
n=23 





    
      Age (years ) a 51 ± 8  51 ± 8 50 ± 9 0.53 
      Males/Females (n) 54/11 20/3 34/8 0.53 
Etiology of cirrhosis (n)     
      Virus-related 38 11 27 0,04 
      Alcoholic 13 4 9  
      Mixed 9 7 2  
      Others 5 1 4  
Child-Pugh class     
      A 4 2 2 0,44 
      B 55 20 35  
      C 6 3 3  
MELD score 13±3 13±2  13±5 0.94 
Ascites rating (n)     0.57 
        None 37 14 23  
        Mild/Moderate 20 8 12  
        Severe 8 3 5  
AST (UI/l) 80 ± 44 79 ± 47 81 ± 42 0.8 
Bilirubin tot.(mg/dl) 4.4 ± 4.8 4.05 ± 4.5 5.2 ± 5.4 0.3 
Albumin (mg/dl) 31.2 ± 4.7 31 ± 3.9 31 ± 5.8 0.83 
Prothrombin time (%) 58 ± 17 56 ± 17 59 ± 15 0.6 
Creatinine (mg/dl) 0.98 ± 0.28 0.98 ± 0.28 0.99 ± 0.29 0.97 
Glucose (mmol/l) 6.6 ± 4.5 6.8 ± 5.6 6.5 ± 3.8 0.87 
Sodium (mEq/l) 137 ± 6 137 ± 5 138 ± 4 0.5 
     
Previous OHE (n) 23    
     One episode of OHE (n) 11    





 All patients underwent neuropsychological assessment comprising 1) an 
extensive paper and pencil psychometric battery, and 2) the computerized SCAN test. 
  
The psychometric tests battery comprised the following paper and pencil tests:  
Trial Making Test A (TMT A), Trial Making Test B (TMT B), Digit Span (DS), 
Phonemic Verbal Fluency (PVF), Symbol Digit Test (SDT), Memory with 
Interference Task at 10 and 30 seconds (ITM 10 and ITM 30) and The Immediate and 
Delayed Story Recall Memory (ISRM and DSRM). The tests were chosen to cover 
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different cognitive domains: attention, memory and executive functions (Table 2). 
Two tests accounted for more than one domain: the Trail Making Test B and The 
Symbol Digit Test. Psychometric tests were expressed as age- and education-adjusted 
Z scores, i.e. in units of standard deviations stratified on the basis of age and 
education level in the reference population of normal individuals. For each test, a Z 
score ≤ –2 was considered abnormal. For each individual, we calculated both the 
number of abnormal tests and the mean Z psychometric index (ZPSI) were 
calculated. ZPSI was used as an overall synthetic index of cognitive performance. 
The computerized Scan test is a digit recognition task based on the Sternberg 
paradigm (111). It has previously been shown to be useful in patients with cirrhosis 
(112). The subject is presented with 36 consecutive pairs of numbers, which may or 
may not have common digits. The subject is asked to press 1 on the keyboard if there 
are digits in common between the two numbers (i.e. 4983, 691) and 3 if there are not 
(i.e. 481, 7562). The number of correct responses, expressed as a percentage of the 
total number of stimuli (accuracy), and the accuracy-adjusted, average ScanRT (ms) 
are calculated.  
MHE was diagnosed in patients with cirrhosis in the pre-LT examination. The 
diagnosis was defined by the presence of 2 or more impaired psychometric tests 
between TMT A, TMT B, SDT and/or abnormal slowing of the EEG, in the absence 
of a known cause of impairment (11). To compare cognitive performance before and 
after LT in patients with MHE we considered, after LT, the alterations on the same 
psychometric test used to detect MHE before LT (at least at two tests altered between 
TMT A, TMT B and SDT). While the detection of MHE was based on three 
psychometric tests (TMT A, TMT B and SDT), we decided to administer a complete 
neuropsychological battery, to assess any possible cognitive abnormality in the post-
transplant course.  
 
Statistical analysis 
Continuous variables are reported as mean ± standard deviation. Categorical 
variables were reported as absolute number and/or percentages. All the 
neuropsychological tests were expressed as age and education-adjusted Z-scores. The 
chi-square test or Fisher’s exact tests were used to study the existence of significant 
differences between nominal variables. Student t test was used to compare means. 
Univariate regression analysis was used to identify those pre-transplant factors that 
were associated with post-transplant cognition. ANOVA for repeat measures was used 
to compare the mean Z score of psychometric tests of patients with a history of prior 
OHE with patients without.  
 
5.4 Aim 4: Modulation of gut microbiota in HE  
Independent batch culture fermentations with controlled pH (6.8) were 
inoculated with fecal samples from six cirrhotic patients (age 66±3.3 years; Child-
Pugh A (n=5) and B (n=1); average MELD score 9±2.8). All patients with cirrhosis 
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did not take any antibiotics for two months prior to collection of the faecal samples, 
had not consumed pre or probiotic supplements.  
Freshly voided stool samples were collected in sterile plastic pots on the day of 
inoculation of the batch vessels. Samples were diluted (1:10 w/w) with sterile 
reduced phosphate buffered saline (PBS) (0.1 M, pH 7.0) and homogenized in a 
stomacher (Seward, Norfolk, UK) at normal speed for 2 min. Each vessel was 
inoculated with 15 ml (10% v/v) of the homogenized fecal slurry. 
 
Batch culture fermentations 
Anaerobic, pH controlled batch culture fermentations were used to assess the 
effect of prebiotic, probiotic and antibiotic on composition of gut microbiota and 
fermentation characteristics. Water jacketed fermenter vessels (300 ml) were 
aseptically filled with 135 ml of presterilized basal nutrient medium. The temperature 
of each batch vessel was maintained at 37°C by means of a circulating water bath. 
The pH was maintained at 6.8 using an Electrolab pH controller. Batch cultures were 
run for a period of 24 h and 5 ml samples were obtained from each vessel at 0, 5, 10 
and 24 h. 
Seven different treatments with lactulose, rifaximin and VSL#3 or their 
combination were performed. Conditions tested: no treatment (ctrl), lactulose (1%), 
rifaximin (616µg/ml), lactulose and rifaximin, VSL#3 (initial[] of 108cell/ml), 
VSL#3 and lactulose,VSL#3 and rifaximin,VSL#3 and lactulose and rifaximin.  
Microbial populations were enumerated using flow cytometry Fluorescent In 
Situ Hybridization (FISH) at 0, 4, 10 and 24 hours. Ammonia concentration was 
determined at 0, 4, 10 and 24 hours. 
Fluorescent in-situ hybridization (FISH)  
Changes in the fecal bacterial populations for each batch were assessed using 
fluorescent in-situ hybridization (FISH). Samples (375 µl) obtained from each vessel 
at each time point were fixed overnight in 1.125 ml of 4% (w/v) filtered 
paraformaldehyde (pH 7.2). The fixed cells were centrifuged at 13,000 g for 5 min, 
washed twice with filtered phosphate buffered saline (PBS) (0.1 M, pH 7.0), 
resuspended in 300 µl of a mixture of PBS/ethanol (1:1 v/v) and stored at −20 °C 
until further analysis. Oligonucleotide probes targeting specific regions of the 
16SrRNA gene labelled with the fluorescent dye Cy 3 were used (Sigma–Aldrich 
Ltd., UK). The bacterial groups were selected based on their predominance and 
contribution to the colonic microbiota. The probes used were specific for total 
bacteria, Bifidobacterium spp., Lactobacillus/Enterococci and Fecalibacterium 







6. RESULTS  
 
6.1 Animal Naming Test for detection of CHE  
 
Standardization sample 
The characteristics of healthy subjects sample are summarized in Table 2. 
Males and females were homogeneously distributed throughout the age classes (χ2= 
2.9, p=0.4); in contrast, an inverse association between age and education levels (χ2 
=58,p<0.001) was detected, as expected, because high education was rare in old 
individuals and low education was rare in young individuals due to the calendar 
effect (since the opportunities for studying increased with time).  
In healthy individuals, the ANT1 and the ANT2 were found to be strictly 
correlated (r=0.88, p<0.01) and both tests were found to be correlated with age and 
education, but not with gender.  
On closer inspection, education produced a roof effect over 8 years, so that 
only subjects with education <8 years were found to list a significantly lower number 
of animals at 1or 2 minutes than subjects with education ≥8 years. Similarly, subjects 
with age>80 years were found to list a significantly lower number of animals than 
subjects≤ 80 years, whereas the effect of age was negligible, if any, in subjects with 
age≤70 years. Therefore, fixing the lower limit of reference at the 2.5th percentile, the 
resulting limits are reported in Table 5. The age-education adjusted equivalent score 
(A-ANT1) is therefore easily obtained, giving a bonus of 5 animals for people with 
education≤7 years and age≤80 years, of 8 animals for people with education ≤7 years 
and age>80 years, and of 2 animals for people with age>80 years and education >7 
years, and considering 12 as the cut off of normality for the A-ANT1. 
However, for simplicity, the following model for a simplified ANT1 equivalent 
score (S-ANT1) was implemented: S-ANT1=ANT1 for all subjects with education ≥ 8 
years, S-ANT1=ANT1+3 for subjects with education<8 years and age≤ 80 years; S-
ANT1 =ANT1+6 for subjects with education<8 years and age>80years. 
 
Table 5. ANT1’s and ANT2’s limits of normality equivalent scores 
Limits of normality ANT1 and ANT2 
 ANT1 ANT2 
 Age≤80 years Age>80 years Age≤80 years Age>80 years 
Primary school 7 4 10 7 
School > 7 years 12 10 19 13 
 Equivalent score 
 A-ANT1 
(limit of reference ≥12) 
Education≤7 years and age Age≤ 80 years: +7 animals 
Education≤7 years and age Age>80 years:  +8 animals 
Education>7 years and Age>80 years:         +2 animals 
 S-ANT1 
(limit of  reference ≥10) 
Education≤7 years and age Age≤ 80 years: +3 animals 





Control group of patients with IBD.  
On average, the S-ANT1 performance was comparable of that of healthy 




Table 6. S-ANT1 in healthy subjects, in patients with IBD and in patients with 







Patients with cirrhosis 
 n=327 
 








    Pooled       MHE             Grade I 
 N=126       n=76               n=50 
 
S-ANT1 23±0.5 a 25±2.5 16±0.7 * 12±0.4*§  13±0.5*§ # 11±0.6*§ # 4±0.9*§° 
 
Abbreviations: HE, hepatic encephalopathy; MHE, minimal hepatic encephalopathy, ANT1, Animal Naming Test at 1 
minute; a mean±standard error  
* p<0.001 versus healthy subjects         (Tukey’s adjustment for multiple comparisons) 
§ p<0.05 versus unimpaired HE             (Tukey’s adjustment for multiple comparisons) 
# p<0.01 MHE vs. grade 1 HE 
° p<0.01 vs unimpaired and vs. CHE   (Tukey’s adjustment for multiple comparisons) 
 
 
Patients with cirrhosis 
The clinical and demographical characteristics of the patients are reported in 
Table 2. One hundred and sixty-nine (52%) patients with cirrhosis were found to be 
unimpaired on PHES, 32 (10%) were found to have OHE on clinical examination 
(n=18 grade 2,  n=14 grade 3), and 126 (38%) were found to have CHE (MHE or 
grade I HE). Of these, 50 (15%) had grade I HE and 76 (23%) had MHE on PHES. 
The S-ANT1 was found to be correlated with MELD score (r=-0.16, p<0.025) and S-
ANT1 was lower in patients with a history of previous OHE than in those who did not 
have OHE (12±0.6 vs. 14±0.5,p<0.03). Adjusting for MELD score, the S-ANT1 was 
comparable in subjects with cirrhosis of different etiology (alcoholic 
cirrhosis=13.6±0.6, viral=13.1±0.5, other etiologies=13.6±0.9; F2,256=0.6,p=0.5). The 
S-ANT1 performance was lower in patients with cirrhosis than in healthy subjects 
(and subjects with IBD), and, within the patients with cirrhosis, the patients with 
CHE resulted in between the unimpaired ones and those with OHE (Table 6). In 
addition, the subjects with grade 1 HE on clinical examination resulted to have lower 
S-ANT1 than those with only MHE on PHES (Table 6).  
The EEG was found to be altered in 42% (n=47) of the 146 patients who 
underwent EEG examination and the CFF was found to be altered in the 24% (n=23) 
of the 95 patients who underwent CFF examination. There were correlations between 
S-ANT1 and EEG spectral parameters (MDF r=0.23 p<0.001; delta relative power r=-
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0.17 p=0.04; theta relative power r=-0.23 p=0.005; beta relative power r=0.26 
p<0.001); however, the S-ANT1 did not result to be related with CFF. 
A-ANT1 ≤ 16 resulted to provide the optimal cut-off to discriminate the 
patients with CHE vs. the unimpaired ones by ROC curve analysis (sensitivity 79%-
CI95% 68-83;specificity 59%-CI95% 51-67). Using the S-ANT1, the optimal cut-off 
value to detect patients with CHE vs. unimpaired ones was S-ANT1<15 on ROC 
curve analysis (sensitivity=83% CI95%=75-89;specificity=47% CI95%= 40-55) (Fig. 1). 
The ROC curves obtained respectively from the A-ANT1 and the S-ANT1 were 
comparable (Fig. 1). In addition, S-ANT1 < 10 was found to have quite satisfying 
values of specificity (84% CI95%=78-90). Sensitivity/specificity, PPV and NPV of the 
S-ANT1 are shown in Table 7. This produced a three step Scoring System of simple 
clinical use, which is easy to memorize (Table 8). 
Applying the above Scoring System based on S-ANT1, 30% (n=97) of patients 
had Score 2, 39% (n=128) had Score 1 and 31% (n=102) had Score 0. This Scoring 
System was found to be correlated with PHES (r=-0.40 p<0.0001) and the MDF of 
the EEG (r=-0.18 p<0.05), but not with CFF (r=0.11,p: n.s). A negative correlation 
was found with Child Pugh score (r=0.22 p<0.01), and a trend for a correlation with 
MELD score (r=0.12 p=0.059). The ANT1 Scoring System was found a good 
predictor of CHE (χ2=15 p=0.0005), also if it was considered in its wider meaning as 
altered PHES/EEG or HE grade I (Table 8).  
 
 




Table 7. Sensitivity/specificity, positive predictive value (PPV) and negative 
predictive value (NPV) of the S-ANT1 
 
 Sensitivity Specificity PPV NPV +LR -LR 
CHE vs. 
unimpaired 
23%(CI95%=16-30) 91%(CI95%=87-95) 66%(CI95%=58-74) 61%(CI95%=52-66) 1.9 1.6 
OHE vs. 
CHE 
72%(CI95%=16-30) 77%(CI95%=12-44) 44%(CI95%=27-61) 92%(CI95%=83-100) 0.8 10.8 
Grade I* vs. 
MHE  
38%(CI95%=5-21) 87%(CI95%=46-75) 66%(CI95%=53-79) 68%(CI95%=55-81) 1.9 0.5 
Grade I* vs. 
unimpaired
+ MHE  
38%(CI95%=26-51) 90%(CI95%=86-94) 43%(CI95%=21-65) 88%(CI95%=73-100) 0.8 7 
 


























Abbreviations: CHE, covert hepatic encephalopathy; OHE, overt hepatic encephalopathy; MHE, minimal hepatic 
encephalopathy; PPV, positive predictive value; NPV, negative predictive value; LR, likehood ratio; EEG, 
electroencephalogram; CFF, Critical Flicker Frequency. * Based on West Haven Criteria 
 
 
Table 8. ANT1 Scoring System 
 
Score S-ANT1 Interpretation 
0 > 15 animals  Probably normal  
(PHES or EEG abnormal=31%) 
1 > 10 and ≤ 15 animals Possibly abnormal  
(PHES or EEG abnormal =55%) 
2 ≤ 10 animals Probably abnormal  
(PHES or EEG abnormal =78%) 
Correction grid*   
If education < 8 
years  
ANT1 row values + 3 animals  
If both education < 8 
years and age > 80 
years 
ANT1 row values + 6 animals  
 
*If patients had less than 8 years of education a bonus of 3 animals should be added to the raw score. If patients had 





The S-ANT1 score resulted to have prognostic value on the risk of a 
breakthrough of OHE in the follow up, and S-ANT1≤10 had also prognostic value on 
the one-year risk of mortality. On multivariate analysis, S-ANT1 score ‘2’ resulted to 
have independent prognostic value on the occurrence of a bout of OHE in addition to 
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previous episodes of OHE (Table 9). Further, the S-ANT1 improved the prognostic 
value of the MELD score on mortality at one year, because the higher numbers of 
animals reported in one minute the lower the risk of death (Table 9). Finally, using S-
ANT1 and the history of previous OHE, a Prognostic Index of the risk of OHE 
(HEPI) could be derived [HEPI =10*EXP (-0.0711 x S-ANT1+0.6826 x previous 
OHE (inserting ‘0’=for no previous OHE and ‘1’ for previous OHE)]. The HEPI was 
found to be a strong predictor of OHE on Cox’s method (p<0.00001). The HEPI is 
about 2 for individuals without previous history of OHE and normal S-ANT1 (giving 
a probability of OHE at 6 months of about 20%), is about 5 for individuals with either 
low S-ANT1 or previous OHE (giving a probability of OHE at 6 months of about 30-
35%), and≥10 for individuals with both low S-ANT1 and previous OHE (giving a 
probability of OHE at six months≥50%).  
 
Table 9. Predictors of breakthrough of OHE and death at one year 
 
Follow up study 
 Risk of breakthrough of OHE Risk of death 
univariate 
model 
MELD: HR=1.06 (CI95%:1.02-1.10),p<0.001 
S-ANT1: HR=0.92 (CI95%:0.88-0.96),p<0.001 
S-ANT1 score‘1’: HR=1.24 (CI95%:0.70-2.18), 
p=0.46 
S-ANT1 score‘2’: HR=2.38 (CI95%:1.39-4.10), 
p<0.001 
Previous bout OHE:HR=2.20(CI95%:1.39-3.48), 
p<0.001 
MELD: HR=1.07 (CI95%:1.02-1.11),p<0.001 
S-ANT1: HR=0.93 (CI95%:0.89-0.98), p<0.001 
S-ANT1 score ‘1’: HR=0.97 (CI95%:0.52-1.80),p=0.93 
S-ANT1 score ‘2’: HR=1.81(CI95%:1.02-3.21),p<0.05 




S-ANT1 score ‘2’: HR=2.10 (CI95%:1.20-3.63), 
p<0.02 
Previous bout OHE: HR=1.79 (CI95%:1.10-2.91), 
p<0.01 
S-ANT: HR=0.95 (CI95%:0.90-0.99),p<0.02 
MELD: HR=1.06 (CI95%:1.02-1.10),p<0.01 
* Variables selected by backward procedure using Newton Raphson algorithm 
 
6.2 Confounders in the detection of CHE  
 
The three groups of patients with liver cirrhosis (alcohol-related, HCV-related 
and non alcohol-HCV related) did not significantly differ regarding liver dysfunction, 
ascites rating and prevalence of diabetes mellitus (Table 10). They differed with 
regard to AST and creatinine level (higher in the HCV-cirrhosis group and in the 
alcohol-cirrhosis group, respectively). The diagnosis of MHE, based on the EEG 
spectral analysis was higher in the alcohol-related cirrhosis group (53% vs 27%; 
p=0,04). Also in the case of MHE detected by the alteration of two psychometric tests 
(27) the prevalence was higher in patients with alcohol-related cirrhosis (53% vs 7% 
in HCV-cirrhosis and 27% in non HCV-alcohol cirrhosis groups; p=0,0005). The 
prevalence of previous episodes of OHE was similar in the three groups, slightly 
higher in the no HCValcohol cirrhosis group but without reaching statistical 






Table 10. Clinical and biochemical variables of patients with liver cirrhosis 
 
 







Non alcohol/HCV (n=30) 
 
 
               p value 
Ascites  rating (n)    0,2 
    None/mild 20 16 17  
    Moderate 7 7 11  
    Severe 3 7 2  
 
HE grading  (n) 
    
0,39 
   Grade 0 26 22 23  
   Grade 1 4 8 7  
 
Child-Pugh class (n) 
    
0,34 
    A 1 0 0  
    B 18 18 23  
    C 8 10 5  
 



















MHE-F b      (%) 2 (7%) 16 (53%)  5 (27%) 0,005 
     
AST (U/l) 101±58 49±23 72±48 0,0005 
Bilirubin (µmol/l)  57±53  88±87 64±8 0,28 
Albumin (mg/dl) 32±5 31±4 31±6 0,71 
Prothrombin time (%) 61±13 56±16 54±18 0,24 
Creatinine (mg/dl) 0.91±0.23 1.20±0.84 0.90 ±0.19 0,07 
     
Diabetes (n) 7(29%) 4 (17%) 3 (12%) 0,29 
 
HE, hepatic encephalopathy; MHE, minimal hepatic encephalopathy 
a
 The diagnosis of MHE was basis on EEG spectral analysis: MDF < 6.8 Hz  or THETA ≥ 35 Hz [25]  




In control subjects, the profile of test performance was homogeneous 
(F8,232=1.6, p=0.11), as expected in subjects where cognition is preserved in all 
domains. In contrast, in patients with cirrhosis it was heterogeneous (F8,712=23.8 
p<0.001), with an interaction condition (healthy normal vs. cirrhosis) per tests 
(F8,1424=6.4 p<0.001) (Fig.2), showing impaired executive functions, evidenced by 
worse performance in PVF and TMT (B-A). In contrast, only a trend for ITM 10 and 




Figure 2. Z scores of psychometric tests in control healthy subjects and in 
patients with cirrhosis. The profile of psychometric test performance is 
homogeneous in control healthy subjects (A) and heterogeneous in patients with 
cirrhosis (B), with massive reduction of the TMT (B-A) and PVF, which reflecting 







The performance of psychometric test was heterogeneous in subjects with 
HCV hepatitis (F8,232=2.7 p=0.008), since it differed across the domains. An 
interaction condition (healthy normal vs. HCV hepatitis) per tests (F8,994=2.4 p<0.02 
Fig 2) was found, showing reduced ITM 10 in subject with HCV hepatitis (p<0.05). 
However, there was no interaction between the factors ‘cirrhosis’ per ‘HCV 
infection’ per tests (F8,928=1.5 p=0.14); indeed, the cognitive profile of patients with 
HCV-related cirrhosis was comparable that of non-alcohol and non-HCV-related 












Figure 3. Psychometric tests performance in patients with HCV hepatitis  and 
HCV related cirrhosis. With respect to healthy controls (A), the subjects with HCV 
hepatitis had reduced ITM 10. No interaction was found between the factor 







The performance of psychometric tests was heterogeneous also in non-
cirrhotic alcohol misusers (F8,232=7.7 p<0.001), with an interaction condition (healthy 
controls vs. non-cirrhotic alcohol misusers) per tests (F8,994=3,9 p<0.01) and 
reduction of PVF, TMT (B-A), ITM 10 and ITM 30 (all p<0.05) (Fig. 4), therefore 
showing a decay in the domains of selection and switching, as well as in working 
memory. An interaction was observed between the factors ‘cirrhosis’ per ‘alcohol 
misuse’ per tests (F8,928=2.5 p<0.01), so that patients with alcoholic cirrhosis showed 
lower performance in PVF, TMT (B-A), ITM 10 and ITM 30 (all p<0.05) compared 











Figure 4. Psychometric tests performance in patients with chronic alcohol 
misuse (A) and cirrhosis alcohol-related (B). With respect to healthy controls (A), 
non-cirrhotic alcohol misusers had reduced PVF, TMT (A-B), ITM 10 and ITM 30. 
(B) Patients with alcoholic cirrhosis showed lower performance of PVF, TMT (B-A), 







At multiple regression analysis,  the overall cognitive performance of 
patients with cirrhosis, expressed like the mean Z score of all psychometric tests 
(MZPT), was shown to be influenced by the etiology of cirrhosis (F16,505=1.7 p<0.05) 
and this effect remained unchanged also after the correction for the MELD score 
(Fig. 5). 













Figure 5. Psychometric performance in patients with cirrhosis, corrected for the 
MELD score. (A) Z scores of psychometric tests are lower in patients with alcoholic 
cirrhosis (F16,504=1.7 p<0.05). (B) Patients with alcohol related cirrhosis showed 
lower MZPT than patients with HCV and non HCV-non alcohol cirrhosis, also in the 








EEG profiles. The MDF, the theta and the beta relative power of quantified EEG 
were influenced by the factor ‘cirrhosis’ (p<0.05) (Table 11). Alcohol misuse per se 
did not influence EEG spectral indices. However, alcohol misuse was associated with 
a trend for reduction of MDF and increase of theta and delta relative powers. HCV 








Table 11. EEG variables in the various groups studied 
 














      
MDF (Hz) 11.36±1.38 11.78±1.63 10.98±0.98 9.59±1.94* 8.96±1.98*a 10.09±1.98*a 
Absolute power (µV2) 89.64±127.96 80.39±84.96 45.13±30.08 153.23±159.74  143.68±100.06  107.50±81.40 
Delta (%)  9.23±9.41 5.64±3.21 7.31±2.57 9.23±9.41 12.78±13.55 a 7.36±3.91 
Theta (%) 14.17±5.81 15.52±12.23 16.10±6.12 28.92±19.62*  34.36±16.96 *a  25.90±17.92 *a 
Alfa (%) 47.24±15.84 47.90±14.13 51.82±12.32 46.85±20.16 38.45±17.91 47.01±16.82 
Beta (%)  29.37±12.43 30.92±14.09 24.48±10.43 14.97±9.56* 14.60±7.91*a 19.71±14.79* 
 
Note: mean values ± SEM. *p < 0.05 vs. Controls; a p<0.05 vs. subjects without cirrhosis and the same exposure 
(alcohol, HCV, or non alcohol/HCV); b p<0.05 vs. subjects with cirrhosis without exposure to alcohol or HCV 
 
Other possible confounders  
Since age and education impinge on cognitive decline, we considered the 
overall cognitive performance adjusted for age and education (MZPT), comparing 
that of the older patients with cirrhosis (4th percentile) to that of the younger patients 
with cirrhosis (1st percentile), adjusting for liver dysfunction and etiology. Three 
educational levels were considered: 5-7 years; 8-12 years and > 13 years. MZPT was 
found to be predicted by education (F2,66=8.1 p<0.001) and etiology (F2,66=4.2 
p<0.02), with a lower performance in alcoholic cirrhosis. While we found an 
addictive risk of low education in explaining low cognitive performance (or, vice 
versa, the protective effect of high education), older age did not seem to be a risk 
factor per se. In contrast to psychometric tests, the EEG indexes did not show an 
association with education or etiology or age.  
The presence of diabetes in patients with cirrhosis was not associated with 
impaired psychometric performance (p=0.29), or low EEG MDF (p=0.33). 
 
 
6.3 Reversibility of Cognitive Impairment after LT  
 
Cognitive function and EEG features before LT  
 The prevalence of altered psychometric paper and pencil tests before LT is 
shown in Table 12 and the spectrum of cognitive and EEG alterations before LT are 
shown in Table 13. Detailed neuropsychological evaluation showed that 42% of 
patients had one or more abnormal cognitive tests and 12% failed six or more tests, 
indicating broad neuropsychological impairment (Table 13). Neuropsychological tests 
before LT documented abnormalities in  several domains; the most highly affected 
were attention and executive function, represented by the TMT B (impaired in 38% 
45 
 
of patients),  the TMT B-A (in the 37%) and the SDT (in the 31%) (Table 12). 
Memory tests were less impaired (DS and ISRM were altered in 5% of patients, 
DSRM in 6%, ITM 10 and ITM 30 respectively in 14% and 11%). The Scan test was 
abnormal in 19 patients (29%) and the EEG was abnormal in 22 patients (34%).  
 MHE was diagnosed in 21 patients (32%) (Table 13). The clinical and 
biochemical characteristics of patients with and without MHE are presented in Table 
4. The two groups were comparable in terms of age, years of education, MELD score. 
23 patients (35%) had a history of OHE; the clinical and biochemical characteristics 
of patients with and without a history of OHE are presented in Table 4 and revealed 
no statistically significant differences in age, gender, presence of diabetes mellitus 
and degree of liver dysfunction. However, there was a statistically significant 
difference in aetiology of cirrhosis, where viral plus alcohol-related aetiology was 
more frequent in the prior OHE group (chi-square, p=0.084) (Table 14). As expected, 
in the group of patients with a history of OHE, MHE was more common (61% vs. 
39%, p=0.03). None of the patients showed OHE at the time of the evaluation before 
LT. Four patients (all of them with prior OHE) had a bout of grade 2 OHE in between 
the assessment and LT, and recovered completely (2 episodes were precipitated by 
constipation, 1 by urinary tract infection and 1 by excessive diuretics). None of the 


























Table 12. Prevalence of abnormalities on psychometric tests and corresponding 
neuropsychological domains in the total sample of patients and according to the 
















p values Pre LT 
No OHE  
(n=42) 
Post LT 
No OHE  
(n=42)  




Prior OHE  
(n=23) 
p values 
Attention TMT A  14 (22%)* 12 (18%) 0,48 2 (6%) 7 (22%) 0,035 10 (43%) 5 (26%) 0,22 
 TMT B  25 (38%) 22 (34%) 0,56 7 (21%) 10 (32%) 0,25 14 (61%) 10 (59%) 0,89 
 TMT B-A 24 (37%) 4 (6%) 0,0001 7 (21%) 0 (0%) 0,0017 13 (57%) 3 (18%) 0,006 
 SDT  20 (31%) 10 (15%) 0,01 7 (21%) 4 (13%) 0,33 10 (43%) 5 (28%) 0,29 
Memory DS  3 (5%) 0 (0%) 0,6 0 (0%) 0 (0%) 1,00 3 (17%) 0 (0%) 0,038 
 ISRM 3 (5%) 1 (2%) 0,25 0 (0%) 0 (0%) 1,00 2 (12%) 0 (0%) 0,086 
 DSRM 4 (6%) 3 (5%) 0,76 0 (0%) 1 (6%) 0,11 3 (18%) 0 (0%) 0,033 
 ITM 10  9 (14%) 5 (8%) 0,18 1 (4%) 2 (6%) 0,67 8 (44%) 3 (17%) 0,047 
 ITM 30  7 (11%) 5 (8%)  0,47 2 (7%) 2 (6%) 0,85 5 (28%) 2 (11%) 0,15 
Executive 
function 
TMT B 25 (38%) 22 (34%) 0,56 7 (21%) 10 (32%) 0,25 14 (61%) 10 (59%) 0,89 
 SDT  20 (31%) 10 (15%) 0,01 7 (21%) 4 (13%) 0,34 10 (43%) 5 (28%) 0,29 
 PVF 9 (14%) 7 (11%) 0,52 4 (14%) 3 (9%) 0,47 5 (28%) 4 (22%) 0,63 
 
NOTE: * Number (percentage) of patients with altered test. Abbreviations: TMT A, Trial Making Test A; TMT B, Trial 
Making Test B; DS, Digit Span; PVF, Phonemic Verbal Fluency; SDT, Symbol Digit Test, ITM 10 and ITM 30, 
Memory with Interference Task at 10 and 30 seconds; ISRM and DSRM, Immediate and Delayed Story Recall 






















Pre LT  (n=65) Post LT (n=65) p values 
Number of altered tests:   <0.05 
      ≥ 1 test 27 (42%)* 15 (23%)  
      ≥ 2 tests 22 (34%) 7 (11%)  
      ≥ 3tests 17 (26%) 5 (8%)  
      ≥ 4 tests 12 (18%) 4 (6%)  
      ≥ 5 tests 9 (14%) 2 (3%)  
      ≥ 6 tests 8 (12%) 0 (0%)  
Scan test 19 (29%) 10 (15%) 0,017 
Cognitive impairment° 19 (30%) 6 (9%) < 0.05 
EEG  22 (34%)  1 (1.5%) < 0.05 
MHE  21 (32%) 7 (11%) < 0.05 
 
NOTE: * Number (percentage) of patients with altered value; ° Cognitive impairment is represented by at least at two 
tests altered between TMT A, TMT B and SDT. Abbreviations: MMSE Mini Mental State Examination; EEG 



















Table 14. Comparison of clinical and biochemical characteristics of patients 





     
 
After LT 




p values Prior OHE 
(n=23) 
No prior OHE 
(n=42) 
p values Delta ZPSI 
Age (years) 50,6  ±  9,9 50,6  ± 8,2 1 51,5± 7,5  50,3± 8,8 0,59 p=0,073 
Sex (M/F) 81%/9% 84%/16% 0,86 87%/13% 82%/18% 0,64  
Age of education 
(years) 




   Viral  
   Alcohol 
   HCV+alcohol 


































Alcohol etiology  6 (29%) 7 (16%) 0,49 8/43% 10/24% 0,11 p=0,04 
MELD score 9,7 ± 4,4 10,8 ± 5,3 0,62 10,6± 4,3 11,3± 5,5 0,59 p=0,18 
Creatinine 
(mg/dl)  
0,9  ± 0,2 1,0  ±  0,3 0,39 0,9± 0,3 0,9± 0,3 0,63 p=0,48 
Bilirubin (mg/dl) 3,8 ± 2,6 4,1 ± 4,5 0,86 4,4± 3,2 4,2± 4,7 0,82 p=0,26 
Diabetes 5 (25%) 6 (15%) 0,33 4 (19%) 6 (18%) 0,93  
Prior OHE 11 (61%) 12 (31%) 0,03    p=0,0014 
> 1 episode of 
prior OHE 
7 (39%) 5 (!3%) 0,05    p=0,0073 
MHE    11 (48%) 7 (26%) 0,03  
NOTE: Mean standard deviation for continuous variables; number of patients (n/%) for categorical variables. 




Cognitive and EEG assessment after LT  
  At the end of follow up, there was a significant cognitive improvement in 
transplanted patients (Table 13). The ZPSI improved significantly (-0.9 ± 0.94 to -0.2 
± 0.47 p<0.05). The degree of improvement in global cognitive function (delta ZPSI) 
was significantly higher in patients with a history of OHE (p=0.0073), and especially 
in those who had had more than one episode of OHE (p=0.0014) (Table 14). A 
relationship was observed between delta ZPSI and the aetiology of cirrhosis, with 
patients with alcohol-related and HCV plus alcohol cirrhosis showing higher 
improvement (F=2.93; p=0.04) (Table 14). There was no association between delta 
ZPSI and age, educational level, MELD score, bilirubin and creatinine levels (Table 
14). After LT, cognitive impairment was significantly lower than prior to LT (30% vs 
9%; p<0.05), but it not disappear completely. To evaluate the possibly predictors of 
the presence of cognitive impairment after LT we performed a univariate regression 
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analysis considering the following variables: age, MELD, prior episodes of OHE, the 
presence of MHE at the time of first evaluation, alcoholic aetiology and diabetes. 
Only age (57±5 vs 50±9 years) was significant (p=0.08). Thus, we did hot perform 
multivariate analysis. 
 The number of psychometric tests altered after LT significantly decreased 
(p<0.05), however, after LT, 23% of patients had more than one test altered and 8% 
had ≥ 5 (Table 13). Furthermore, alterations in those psychometric tests used to detect 
MHE were still present in some patients after LT. Respectively, the TMT A was 
altered in the 18% of patients after LT vs the 22% before LT (p=0.48) , TMT B in the 
34% vs 38% (p=0.55) and the SDT the 6% vs 37% (p=0.01) (Table 12). 
 Quantified EEG showed a significant marked improvement: both MDF and 
relative power of theta significantly improved (10.8±0.66 vs. 9.14±1.8 Hz and 
17.5±5.3 vs. 30±16.7% respectively; all p<0.001). The EEG normalized in the 99% of 
patients and only one patient remained unchanged and abnormal.    
 
Relation with previous episodes of OHE 
 Patients with a history of OHE showed worse cognitive performance before LT 
and greater cognitive improvement after LT (p< 0.01) compared to their counterparts 
with a negative history (overall mean Z score -1.45 ± 1.14 vs -0.49 ± 0.55 p< 0.001) 
(Fig. 6). Their performance remained slightly worse than that of patients without a 
history of OHE, but still within the normal range (overall mean Z score -0.41±0.47 vs 
-0.11±0.50; p< 0.01) (Fig. 6). Before LT, patients with a history of OHE showed a 
worse performance in all psychometric tests, and thus in several cognitive domain: 
attention, memory and executive functions (p<0.001) (Fig. 7). After LT, both groups 
showed considerable improvement in almost all psychometric tests, except TMT A 
(mean Z score after LT -0.17± 1.15  in the no-Prior OHE group vs -0.55±0.89 in the 
Prior-OHE group), the TMT B (-1.38±1.47  vs. -2.28±1.24 p<0.05 ), the TMT B-A (-
0.13± 0.9 vs. -0.58± 1.35). Patients with a history of OHE showed a significant 
improvement after LT in those psychometric tests exploring memory function 
(p<0.001), indeed almost all patients normalized (Table 13); in contrast, their 
performance in those tests exploring attention and executive functions was lower than 
patients without a history of OHE (p<0.001) and they did not improve significantly 
(TMT B -2.3±1.24 vs -1.4±1.5; SDT -0.6±1.2 vs -0.01± 0.9; both p<0.05) (Fig. 7).  
 Patients with a history of OHE also showed more significant EEG slowing 
before LT than their counterparts with a negative history (MDF 8.8 ± 1.9 vs. 9.6 ± 1.6 
Hz; theta relative power 31.8±15.9 Hz vs 26.7±15.3 Hz) without reaching statistical 
significance (p=0.36). After LT the EEG became comparable in the two groups (MDF 









Figure 6. Comparison of cognitive and EEG performance between prior-OHE 
group and No prior-OHE group before and 9-12 months after LT. (A) Before LT 
the overall Z score of all psychometric tests (ZPSI) was significantly lower in the 
prior-OHE group (-1.45 ± 1.14 vs -0.49 ± 0.55 p<0.001) and had a greater 
improvement after LT than No prior-OHE group but their performance remain lower 
(0.41±0.47 vs -0.11±0.50; p< 0.01). (B) EEG spectral analysis: before LT the MDF 
was lower in the prior-OHE group (MDF 8.8 ± 1.9 vs 9.6 ± 1.6 Hz p=0.36) and after 

















Figure 7. Cognitive function before and after LT, according to the presence of a 
history of OHE. (A) and (C) Cognitive domain of attention (explored by TMT A, 
TMT B, TMT B-A, SDT) and executive function (explored by TMT B, SDT and 
PVF) were more impaired before LT in patients with prior-OHE, after LT their 
performance remained lower than patients without prior-OHE. (B) Cognitive domain 
of memory (explored by DS, ISRM, DSRM, ITM 10 and ITM 30), before LT, were 
more impaired in prior-OHE patients but after LT their performance became 
















Three-monthly cognitive and EEG assessment after LT  
In a subgroup of 11 patients evaluated every three months after LT, the ZPSI 
slightly worsened immediately after LT and subsequently, steadily improved (Fig.8). 
ZPSI at 9 and 12 months was significantly better than at 3 months (p<0.05 and < 
0.001 respectively). On EEG spectral analysis, the MDF remained unchanged at 3 
months and significantly improved from 6 months onwards (p<0.001). Patients who 
had experienced previous episodes of OHE showed worse EEG profile than their 
counterparts with a  negative history at all time points, although statistical 
significance was not reached (p=0.75). 
 
 
Figure 8. Neuropsychological and EEG performance prior to and at 3, 6, 9 and 
12 months after LT in a subgroup of 11 patients. (A) The overall Z score of 
psychometric tests worsened at 3 months after LT and improved from 6 months 
onward. Cognitive performance (ZPSI) at 9 and 12 months was significantly better 
than a 3 months (p<0.05 and < 0.001 respectively).(B) At the EEG spectral analysis 
the MDF remained unchanged at 3 months, steadily improved at 6 months and then 











6.4 Modulation of gut microbiota in HE  
 
Bacterial enumeration 
Lactulose treatment significantly increased total bacteria, Bifidobacteria and 
Fecalibacterium prausnitzii after 5 hours (p≤0.05) (Fig.9); in contrast Rifaximin and 
VSL#3 have no significant effect. After 24 hours the combination of 
lactulose/Rifaximine/VSL#3 significantly increased total bacteria and Bifidobacteria. 




Figure 9. Average bacteria count differences, between times 5, 10, 24 and 0 for the 




Average bacteria count differences, between times 5, 10, 24 and 0 for the considered FISH probes 





Ammonia level assay 
At time 5 h, lactulose significanly reduced NH4+, whereas rifaximin had no 
significant effect. Rifaximin reduced NH4+ at time 24 h, also in combination with 
lactulose (Fig. 10). VSL#3 alone had never significant affect in reducing NH4+, 
whereas at 24 h in combination with lactulose and rifaximin reduced significantly 
NH4+ (Fig. 10).  
Figure 10. NH4+ concentration assessed by colorimetric method on the batch culture 
fermentation supernatant (mean±sd, n=6, in triplicates) 
 











This study analysed various aspects of hepatic encephalopathy, focusing on its 
mildest form, which is called Covert HE. In particular, a new tool to screen for CHE 
in patients with cirrhosis, the role of possible confounders in the detection of CHE, 
the reversibility of cognitive impairment owned by CHE after liver transplantation 
and the modulation of gut microbiota by HE treatments was analized. More in detail 
this study: 1) investigated the applicability of the Animal Naming Test in patients 
with cirrhosis with various expression of HE, founding that the ANT1 was an easy 
first-line tool to detect covert HE, simple to score and closely associated with the 
degree of HE and risk of bouts of OHE in the follow up; 2) demonstrated that a 
history of alcohol misuse and HCV infection hamper cognition, where alcohol was 
also found to have a synergistic role with cirrhosis in compromising cognitive 
function and thus should be considered in the diagnosis of CHE; 3) showed that both 
cognitive dysfunction and EEG measures significantly improved one year after 
transplantation but cognitive impairment did not disappear completely; patients with 
previous OHE had greater improvement one year after transplantation, but their 
overall cognitive performance remained slightly lower than that of the patients 
without previous OHE; 4) showed the beneficial effects in gut microbiota during HE 
treatment, by a strong increase in beneficial bacteria, reduction of ammonia and 
regulation of metabolite production using lactulose treatment and its combination 
with Rifaximin and VSL#3.  
In order to investigate the usefulness of the ANT to detect Covert HE, firsly we 
standardized the ANT in healthy subjects, obtaining the resulting thresholds of 
normality. The values of reference for ANT in healthy subjects from our sample 
closely corresponded to those derived from standardization samples of thousands of 
individuals from Italian population and to be dependent of age and education 
(113,114,115). In addition, the reference values for the ANT that were found in our 
study are perfectly in line with wide epidemiological studies in many Western 
Countries: Netherland (116), Spain (117), Portugal (118), France (119), Sweden 
(120), Canada (121,122) and USA. Notably, animal fluency was found to be 
independent of gender in agreement with the majority of studies with the exception of 
the ones by Rosselli M et al. (123) and Raoux N. et al. (119). This is an advantage in 
comparison with the semantic verbal fluency for other categories of objects were 
found to be influenced also by gender, as it is reasonable for categories of objects 
with which there is different familiarity between males and females. The strict 
relationship between ANT1 and ANT2, that was proved, justify the use of the only 
ANT1 in clinical practice, for simplicity. Further, the study of the features of ANT1 in 
relation to education and age showed relevant ceiling effects concerning education 
(which significantly influenced the results only in very low educated subjects) and 
age (which significantly influence the results only in relevantly aged people). 
Therefore, a simplified adjustment of ANT1 for age and education was possible (S-
ANT1), avoiding the complex standardization system that is usually required for 
psychometric testing. The agreement between our standardization and previous 
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studies on ANT strengthens the rationale of the proposal of two thresholds of 10 and 
15 animals in one minute for the S-ANT1. The sample of patients with cirrhosis that 
we studied was rather typical for subjects referred to a tertiary care center, with a 
prevalence of CHE of 38% (124) and with prevalence on patients with viral-related 
cirrhosis slightly higher than the one of patients with alcoholic cirrhosis as is typical 
of South Europe. The S-ANT1 resulted very easy to administer, without any complain 
by the patients, and rapidly provided a piece of information correlated with the ones 
obtainable by much more cumbersome techniques, such as paper and pencil 
psychometrics or quantified EEG, even though the cognitive domain explored by the 
ANT1 concerns semantic fluency which, in principle, should not be the more proper 
to detect the first cognitive defects caused by HE (12). However, if the goal of the 
examiner is to screen for a degree of HE that is just before frank disorientation, the 
use of a widely applicable test is reasonable and relatively low sensitivity can be 
preferred. Notably, despite the ANT1 was not chosen as a tool of extreme sensitivity, 
also patients with cirrhosis who had PHES>-4 showed a lower ANT1 performance 
than healthy subjects or subjects with IBD. This finding was also confirmed after 
excluding individuals with a history of alcohol misuse, which may act as a 
confounder in the assessment of cognitive performance in patients with cirrhosis. At 
any rate, a slowing of cognitive processes in patients with cirrhosis even before 
reaching the threshold for MHE was also observed in other previous studies (125) 
and supports the idea of a continuous spectrum of cognitive decline in patients with 
cirrhosis (126). In addition, the lower performance of the S-ANT1 in patients with 
MHE compared with those with grade 1 HE suggests the heterogeneity of patients 
labeled as having CHE and provides evidence that the S-ANT1 can detect it. An 
adequate performance of the ANT1, which is a semantic fluency test, requires 
efficient organization of verbal retrieval and recall, as well as self-monitoring aspects 
of cognition (the participant must keep track of responses already given), effortful 
self-initiation, and inhibition of responses when appropriate (127) and these cognitive 
skills requires not only memory abilities, but efficient executive functions. Therefore, 
it is not surprising that the presence of CHE, which it is well-know to impaired 
executive functions (128), would affect semantic fluency. As well as mostly 
recommended neuropsychological tools using to diagnose CHE, i.e. the PSE-
syndrome test battery, the Inhibitory Control Test (ICT) and the Scan battery, the 
ANT1 explores cognitive functions related to prefrontal cortex/anterior cortical areas, 
which are particularly vulnerable in CHE. Accordingly, the use of ANT1 results to be 
legitimate, in principle, as a simple tool for at least first-level assessment CHE in 
patients with cirrhosis. This was further proved by: i) the correlation of ANT1 with 
liver dysfunction (MELD score), ii) the lower values of ANT1 in subjects with a 
history of previous bouts of OHE, iii) the correlation with PHES and the quantified 
EEG. The lack of a correlation between the ANT1 and the CFF might indicate that 
CFF reflects a psycho-physiological domain poorly related to semantic fluency, thus 
supporting the opinion that high-quality assessment of CHE is preferably 
multidimensional. Notably, the S-ANT1 at a threshold of 10 animals and 15 animals 
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(with specificity of 84 % and sensitivity of 83%, respectively) was able to provide a 
good classification criterion and produce a meaningful Scoring System for clinical 
practice. Further, the threshold of 10 animals was found to have prognostic value on 
the risk of bouts of OHE in the follow up, which is additive to that of a history of 
previous overt HE. A prognostic index on the risk of OHE (HEPI) composing the 
information obtained by S-ANT1 and the history of previous OHE was also computed 
and resulted to be effective. Possibly, even some prognostication about survival 
seemed to be possible. However, it should be validated in independent prospective 
studies in other populations. Thus, the S-ANT1 Scoring System resulted to be a useful 
and easy
 
tool for first-line assessment of HE in clinical practice, at least where 
accurate formal neuropsychological testing and/or neurophysiological tools are not 
available.  
Investigating the role of confounders in the detection of covert HE, this study 
confirmed that cirrhosis per se, and therefore HE, is the most relevant factor 
hampering cognition and, on closer inspection, executive function in patients with 
HCV-, alcohol-related and non-alcohol/non-HCV cirrhosis groups. At any rate, also a 
history of alcohol misuse and HCV infection were found to hamper cognition. Both 
alcohol and HCV impinged on working memory, and alcohol impinged on executive 
function. Alcohol was found to have a synergistic role with cirrhosis in 
compromising cognitive function. The EEG was considerably influenced by cirrhosis 
per se, thus supporting its role in detecting MHE. Alcohol misuse slightly worsened 
EEG findings in patients with cirrhosis; in contrast, HCV infection had no additive 
effect. Consequently, the diagnosis of MHE, based on both EEG spectral analysis and 
psychometric tests was more common in the alcohol-related cirrhosis group. The 
finding that in patients with cirrhosis, regardless of other confounders, the most 
impaired tests were TMT (B-A) and PVF is in agreement with previous studies 
suggesting that prefrontal cortex – and thus executive function – is particularly 
vulnerable in these patients (13). This is supported by neuroimaging data (10), and 
suggests the presence of a disorder of the prefrontal/anterior cingulate cortex and 
basal ganglia circuits. This finding also supports the present consensus on the 
neuropsychological tools to be used to diagnose MHE, i.e. Psychometric Hepatic 
encephalopathy score (PHES), which studies cognitive functions related to ‘anterior’ 
rather than ‘posterior’ cortical areas, as well as the Scan battery, the Inhibitory 
Control Test (ICT) and the Stroop test. In contrast, the good performance in verbal 
memory tests concerning the recall of a short story explains the apparent cognitive 
normality of several cirrhotic patients on routine clinical interview, where only verbal 
abilities and memory are required. The finding that non-cirrhotic alcoholic misusers 
showed an impairment in PVF, TMT (B-A), IMT 10 and IMT 30 is in accordance 
with the ‘Frontal lobe hypothesis’, stating that chronic alcohol misuse impairs 
executive functions. More precisely, cognitive flexibility, speed in the allocation of 
attentional resources, shifting ability, speed in information processing, inhibition of 
perseveration errors, perceptual motor speed, abstraction and planning abilities, and 
suppression of irrelevant information, which are all related to prefrontal cortex 
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functioning (64). Indeed, the TMT (B-A) reflects the extra cost of performing a test 
(TMT B) that has a higher requirements in terms of switching and sustained attention 
compared to TMT A. Switching and sustained attention, as well as PVF, pertain to 
prefrontal cortex function. The effect on IMT 10 and IMT 30 concerns working 
memory in a verbal task that also implicates prefrontal cortical function. The 
observation that patients with alcohol-related cirrhosis exhibited worse performance 
in PVF, TMT (B-A), ITM 10 and ITM 30 is in agreement with studies suggesting that 
chronic alcohol misuse has additive damaging effect on the brain of patients with 
cirrhosis (128). This finding suggests that the diagnosis of MHE with psychometric 
tests sensitive to prefrontal dysfunction, such as the ICT, the Stroop and the Scan 
tests might be biased by chronic alcohol consumption. Notably, the PHES – i.e. the 
most accredited tool for the detection of MHE (51)– also reflects prefrontal functions 
and thus might be biased by alcohol misuse, at least to some extent. Recently, 
however, Goldbecker et al. (129) produced data suggesting that the confounding 
effect of alcohol misuse on PHES and ICT is negligible. The effect of HCV infection 
was significant on working memory, in that patients with HCV hepatitis had reduced 
ITM 10 compared to healthy subjects. This finding is in agreement with those of 
Forton et al. (130), who reported impairment in working memory, and with 
subsequent, similar observations by Weissenborn et al. (131) and Fontana et al. (132). 
These might be caused by HCV brain colonization (65) or, indirectly, by pro-
inflammatory cytokines activation. HCV infection did not have a confounding effect 
in patients with cirrhosis, in agreement with the study by Cordoba et al. (67). This 
may relate to the fact that in these patients any direct effect of HCV might be masked 
by the more relevant impact of cirrhosis and HE per se. Cognition as a whole was 
also influenced by education in patients with cirrhosis, even if education-adjusted 
norms were used. This suggests that highly educated patients may have higher 
resilience, because of a higher cognitive reserve and that they may maintain adequate 
cognition despite brain damage, as observed in Alzheimer Disease (133). The finding 
that quantified EEG indices were found considerably influenced by the factor 
‘cirrhosis’ and only marginally by alcohol misuse per se, is in line with  previous 
findings (7).  
Looking on the effects of successful liver transplant on cognitive function and 
EEG features, this study showed, firstly, that both cognitive dysfunction and EEG 
measures significantly improved one year after transplantation but, despite the 
significant improvement, cognitive impairment did not disappear completely, while 
the EEG normalized in almost all patients. Secondly, patients with previous OHE had 
worse both psychometric and EEG performance before LT and greater improvement 
one year after transplantation, but their overall cognitive performance remained 
slightly lower than that of the patients without previous OHE. Thirdly, the group of 
patients who were evaluated every three months showed early worsening of 
psychometric performance and stepwise psychometric improvement from 6 months 
onward, while the EEG ameliorated from 3 months and remained substantially stable 
from 6 months onward. At the time of the assessment before LT, our liver transplant 
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candidates showed impairment in several domains and the most highly affected ones 
were attention and executive functions, while memory tests were less impaired. In 
accordance with previous studies (134), MHE had a high prevalence in our sample of 
patients (32%) and a relevant proportion of MHE patients (61%) had had previous 
episodes of OHE. To detect cognitive alterations, we used several paper and pencil 
tests and the Scan test, a well validated computerized test, previously proved to be a 
good index of cognitive impairment in cirrhotic patients for its ability to explore 
executive functions and response speed, which are crucial features of MHE. At the 
second assessment, that was performed 9-12 months after LT, cognitive performance 
improved significantly but, nonetheless, the improvement was not generalized to all 
cognitive domains, in line with previous studies (14), so that some cognitive 
impairment was still present in the 9% of patients. After having excluded from our 
sample the patients who had developed major neurological damage, our results 
showed that the cognitive improvement was more pronounced in those patients who 
had had prior OHE, in particular in those who had had more than one episode of 
OHE. This finding may be not surprising, considering that, as per definition, liver 
transplant should remove HE. However, their performance remained slightly 
impaired, notwithstanding the patients with a history of OHE showed greater 
cognitive improvement after LT compared to their counterparts with a negative 
history. A possible explanation could be the maintenance of slight brain damage 
resulting from bouts of OHE. At this regard, it has been reported that HE may cause 
brain damage, including neuronal loss, and animal models provide convincing 
evidence that several neuronal cell death mechanisms are activated in HE (75). 
Despite this, the loss of neurons resulting from episodic HE seems to be mild. 
Nevertheless, brain tissue loss, even when it is mild, can produce a decline in 
cognitive function, as was suggested by the correlation between brain atrophy and 
psychometric test results (135). In addition to a direct link to HE per se, studies in 
experimental animal models provide convincing evidence that neuronal cell death 
mechanisms similar to those established in stroke and traumatic brain injury are 
activated in brain by liver failure per se. An alternative hypothesis is that subjects 
with other factors impinging on brain function, such as the presence of brain atrophy 
of any reason (128) or slight brain damage resulting from chronic alcohol misuse, 
HCV infection, vitamin or other micro-nutrient deficiency, diabetes etc. present 
residual cognitive impairment after LT, since this was not caused by liver disease per 
se, and, therefore could not be reversed changing the liver. In addition, such slightly 
damaged brain might have been more susceptible to the action of the mechanism 
causing HE, so that OHE might have occurred more easily. Another interesting 
finding is that, one year after LT, both patients with and without a history of OHE 
showed considerable improvement in almost all psychometric tests, except in TMT A 
and TMT B, which resulted to be the most impaired tests after transplantation. This 
might mean   that attention and executive functions are less susceptible to the 
removal of the cirrhotic liver. So other confounders could affect the brain, 
independently of HE. We know that alcohol impairs cognition and causes brain 
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atrophy, which affects mostly the frontal lobes and the cerebellum, but in our sample 
it did not seem to have significant impact. Another hypothesis is that other factors, 
like the immunosuppressive therapy, play a role in maintaining lower performance in 
attention and executive functions.Age was found to be the only likely predictor of 
cognitive dysfunction one year after transplantation. Aging is associated with the 
enlargement of brain ventricles and with the occurrence of white matter lesions that, 
in turn, are closely associated with the development of mild cognitive impairment and 
dementia (136). Furthermore, previous studies have shown that the size of brain 
ventricles in cirrhotic patients after LT is larger than that of controls (135), 
supporting the notion that cirrhosis acts synergically with aging to cause central brain 
atrophy, and consequent enlargement of brain ventricles (128). Similar to cognitive 
performance, quantitative EEG resulted altered in 22 patients (34%) before LT, but, 
differently from psychometric performance, the EEG showed a significant marked 
improvement and normalized in the 99% of patients, one year after LT. Only in one 
patient the EEG remained unchanged with respect to the baseline. This observation is 
in line with the one by Ciancio et al (137), who found that psychometric performance 
of transplant recipients does not improve as well as the EEG does. A key question is 
why quantified EEG improves massively after transplantation while the cognitive 
performance is not complete. One explanation is provided by the fact that the EEG 
reflects the oscillation of postsynaptic potentials of pyramidal cortical cells. This is 
sensitive to the influence of energy-providing metabolic pathways, electrolyte 
balance and the clearance of toxic substances. Therefore, it is not surprising that after 
LT, and thus after the removal of pathogenic metabolic factors related to the presence 
of cirrhosis, electrogenesis was normalized. In contrast, psychometric tests 
investigate cognition, which is an integrated complex of functions, influenced by 
factors such as age, education, type of job (blue collars/white collars), subjective 
‘intelligence’ and connectivity across brain areas. All such factors are substantially 
independent of liver function and cannot be modified by the removal/replacement of 
the cirrhotic liver. In addition, cognitive impairment in patients with liver cirrhosis 
may have a different origin, as mentioned before. Deficiencies of water-soluble 
vitamins, in particularly thiamine, and minerals (zinc, magnesium, and iron) can 
produce changes in mental function (138). Also, inflammation is a factor causing of 
cognitive abnormalities. Montagnese et al. (139) showed that C reactive protein and 
TNFα concentrations were independent predictors of abnormal psychometric tests, 
but not of EEG alterations, in patients with cirrhosis this suggesting that 
neuropsychological and EEG abnormalities have partially different biochemical 
correlates. Furthermore, patients with a history of OHE showed more EEG slowing 
before LT than their counterparts with a negative history but, differently from 
psychometric performance, after LT the EEG became comparable in the two groups. 
This represents a further proof that the discrepancies between EEG and psychometric 
abnormalities, often observed in patients with cirrhosis depend, at least to some 
extent, on the different pathways leading to such abnormalities. In fact, as mentioned 
before, while the EEG reflects the cortical electric activity. Psychometric tests 
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measure cognitive function, which reflects much more complex and integrated 
phenomena. Another important finding of this study is the worsening of the overall 
cognitive performance immediately after transplant (at 3 months). This might be 
explained by the enormous impact that the transplant procedure, high dose of 
immunosuppressant therapy and surgery complications have on patients.  From 3 
months onwards, psychometric and EEG performances improved significantly. These 
findings seem to suggest that LT is able to significantly improve patients’ cognitive 
function in the long term, despite the seriousness of surgery, possible perioperative 
complications, and the neurotoxicity of the immunosuppressant therapy.  
In order to evaluate microbial modulation by prebiotic, antibiotic and probiotic 
treatment in stool samples of cirrhotic patients which were inoculeted in a 24-hour 
batch culture fermentations model at controlled pH (6.8), this studied showed that 
ammonia production is reduced by all the treatments in a time dependent and 
combination manner, except for VSL#3 alone. In effect, VSL#3 ammonia removal 
was augmented by the presence of prebiotic and antibiotic. Over 24 hours ammonia 
removal was retained although the efficacy of lactulose was greater at Time 5 and 
Time 10. Thus ammonia reduction appears to be directly linked to increase in relative 
abundance in Bifidobacteria, better induced by prebiotic and antibiotic. This was in 
line with previous studies that demostrated that probiotics and synbiotics may exhibit 
efficacy in the treatment of HE by modulating the gut microbiota. They improve 
derangement in microbiota by decreasing the counts of pathogenic bacteria and thus 
improving the endotoxemia, HE and the liver disease (105). Several mechanisms may 
be involved for such improvement and may include: (i) modulation of the gut 
microbiota may reduce total ammonia in the portal blood by decreasing bacterial 
urease activity, decreasing ammonia absorption by decreasing pH, decreasing 
intestinal permeability, and by improving nutritional status of gut epithelium, (ii) they 
may decrease endotoxemia and proinflammatory milieu resulting in improvement in 
inflammation and oxidative stress, and liver disease severity, and finally (iii) they 
may decreasing uptake of other toxins, such as, indoles, oxindoles, phenols, 
mercaptons, etc. (140). However, opinion is divided on the clinical significance of 
these apparent benefits, with one recent systematic review concluding that probiotics 
had a clinical benefit (141), whereas another concluded that although probiotics 
appeared to exert a significant effect on blood ammonia levels, probiotics were not 
effective against clinically meaningful end points (142) It should be noted that a 
separate systematic review that focused exclusively on MHE concluded that 
prebiotics, probiotics, and synbiotics were effective for this indication, but that 
lactulose was superior to both probiotics and synbiotics (99). Each of the major 
reviews on the topic be moaned the challenges that the interpretation of available data 
presented, in large part because of limitations in study design and performance.  
The effect of treatments on Fecalibacterium prausnitzii was also analysed in 
this study, since recently, it has been demonstrated that levels of F. prausnitzii, a 
major member of the Clostridium leptum group (143) and one of the most prevalent 
bacteria within the human gut, decreases significantly in patients affected by liver 
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cirrhosis (26). Therefore, it has been suggested that F. prausnitzii could have a role in 
gut homeostasis, taking into account its immunomodulatory activities (144). 
Rifaximin alone had no significant effect on major bacterial groups and these results 
are in agreement with those obtained in a previous study by Bajaj et al in patients 
with cirrhosis (103). Rifaximin was associated with improved cognitive performance 
and reduction in endotoxemia in patients with cirrhosis and MHE but only modest 
change in the stool microbiota characterization with a modest reduction in 
Veillonellaceae and a trend towards increased Eubacteriaceae, without an overall 
significant change in microbiota composition at the phylum or order level (103). 
Another interesting study of the same group showed that there was no significant 
difference in the stool flora between patients with HE on lactulose compared with 
those additionally on rifaximin (43). Thus this study showed that gut microbiota 
modulation is a potential target for relieving the symptoms of HE by regulating 
colonic ammonia production. Combination strategy, with Bifidobacteria increase, 
represents the best ammonia reducing condition. In general lack of a direct 
correlation between microbial modification and ammonia reduction for the tested 
treatments, suggest a modulation in ammonia production rather than increased size of 
the “colonic ammonia sink” via microbial biomass alone, as a possible mode of 
action. The data pave the way to further investigations on gut metabolic activity and 



























8. CONCLUSIONS  
 
In conclusion, the present study showed that:  
 
1) The S-ANT1 is an easy and useful tool to for first-line assessment of HE that is 
related to more complex techniques and has prognostic implications;  
2) HCV infection, alcohol misuse and low educational level are risk factors for 
cognitive dysfunction. Alcohol misuse and low educational level had a synergistic 
effect with cirrhosis, and thus they should be considered when testing for MHE; 
3) Cognitive and EEG performance significantly improved one year after LT, but 
while the EEG normalized in the 99% of patients, cognitive dysfunction did not fully 
recover. A history of OHE is associated with lower cognitive performance one year 
after LT, despite cognitive improvement is relevant. Therefore, this study has added 
to our awareness the risk of cognitive persistent deficit associated with a history of 
OHE before LT.  
4) Microbial modulation by prebiotic, antibiotic and probiotic treatment differently 
affect the population dynamics and metabolism. The strong increase in beneficial 
bacteria, reduction of ammonia and regulation of metabolite production seen using 
lactulose and its combination with VSL#3, emphasize the importance of gut 
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